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Growing adoption of health information technologies is allowing healthcare 
providers to capture and store enormous amounts of patient data. In order to effectively 
use this data to improve healthcare outcomes and processes, clinicians need to identify 
the relevant measures and apply the correct analysis methods for the type of data at hand. 
In this dissertation, we present various data mining and statistical methods that could be 
applied to the type of datasets that are found in healthcare research. We discuss the 
process of identification of appropriate measures and statistical tools, the analysis and 
validation of mathematical models, and the interpretation of results to improve healthcare 
quality and safety.  
We illustrate the application of statistics and data mining techniques on three real-
world healthcare datasets. In the first chapter, we develop a new method to assess 
hydration status using breath samples. Through analysis of the more than 300 volatile 
organic compounds contained in human breath, we aim to identify markers of hydration. 
In the second chapter, we evaluate the impact of the implementation of an electronic 
medical record system on the rate of inpatient medication errors and adverse drug events. 
The objective is to understand the impact on patient safety of different information 
technologies in a specific environment (inpatient pediatrics) and to provide 
recommendations on how to correctly analyze count data with a large amount of zeros. In 
the last chapter, we develop a mathematical model to predict the probability of 
developing post-operative nausea and vomiting based on patient demographics and 
clinical history, and to identify the group of patients at high-risk.
1 
CHAPTER 1 : INTRODUCTION 
 
 The growing adoption of information technologies in healthcare and the 
availability of more patient data and related healthcare variables provide new 
opportunities for using analytics to impact health outcomes. Nowadays, most healthcare 
organizations have some type of healthcare information technology in place (e.g. EMR, 
CPOE, eMAR), which allows them to measure and capture patient data in real time and 
at the point the care. As a result, providers have at their disposition enormous amounts of 
data, which they need to turn into useful information and knowledge that can gear 
towards improving health outcomes.  
Statistical methods such as predictive modeling and data mining are very useful to 
analyze and interpret the type of datasets found in healthcare research. The research 
presented here endeavors to expand the knowledge in this area by examining different 
approaches to the analysis of three healthcare problems. In the first study, we use data 
mining methods to assess hydration status using breath samples. Through analysis of the 
more than 300 volatile organic compounds contained in human breath, we aim to identify 
markers of hydration. For the second problem, we develop a mathematical model to 
evaluate the impact of an electronic medical record system on the occurrence of 
medication errors and adverse drug events in a pediatric inpatient setting. In the third 
study, we apply predictive modeling to estimate the patients’ probability of developing 
post-operative nausea and vomiting based on patient demographics and clinical history.  
Finally, a more practical objective of this dissertation is to advice practitioners which 
statistical model works well for a specific context or data.  
2 
CHAPTER 2 : ASSESSMENT OF HYDRATION STATUS THROUGH 
BREATH ANALYSIS 
 
2.1 Literature review 
 The literature review will explore current methods for assessment of human 
hydration, advances on breath analysis and from that, describe the research needs in the 
area. 
2.1.1 Hydration assessment 
About 63% of the human body mass is water, which is essential for metabolism, 
temperature regulation and other physiological processes that contribute to good health. 
Dietary variations, illnesses, strenuous labor, exercise, among other daily activities can 
alter the normal water requirements for an individual. Even a minimal dehydration of -
1% or -2% of body mass can have a negative impact on cognitive function, alertness and 
exercise performance [1]. At the extreme, acute dehydration, either intentional (e.g., in 
sports competitions to reach a certain weight) or unintentional, presents a significant 
health risk that might even result in death [2]. However, increasing evidence indicates 
that mild dehydration may also account for the development of various morbidities [3]. 
At the same time, good hydration has been shown to reduce the risk of chronic diseases 
such as constipation, exercise asthma, hyperglycemia, among others [4]. Thus, the 
importance of proper hydration and of using reliable and accurate methods to monitor 
and evaluate even small changes in human hydration levels becomes evident [1, 2]. 
The following definitions will be used in this chapter [1]: 
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• Total body water (TBW) is the fluid that occupies intracellular and extracellular 
spaces. 
• Extracellular volume (ECV) is the fluid outside of cells, including the interstitial fluid 
and plasma water, and comprises about 0.2 L/kg (24.9%) of body mass.  
• Intracellular volume (ICV) is the fluid within tissue cells, comprising about 0.4 L/kg 
(38.4%) of body mass.  
• Plasma volume (PV) is the liquid portion of the blood, which makes up about 5% of 
body mass.  
• Interstitial fluid (ISF) is the fluid located in the spaces between tissue cells with a 
chemical composition similar to that of lymph; it is usually calculated as ECV-PV, 
and makes up about 21% of body mass.  
• An electrolyte is any compound that, in solution, conducts electricity and is 
decomposed (electrolyzed) by it; i.e., an ionizable substance in solution.  
• Osmolality is the concentration of a solution expressed in miliosmoles of solute 
particles per kilogram of water. 
• Euhydration can be defined as “normal body water content” [5] 
• Dehydration refers to the process of losing water from the body [6] 
• Rehydration is the process of gaining body water [6] 
• Hyperhydration refers to the state that exists when ingested fluid temporarily increase 
total body water above the average basal level [5] 
• Hypohydration is a state of being in negative water balance (water deficit) [6] 
• Urine specific gravity (Usg) is a measure of the ratio between the density of urine and 
the density of water [7] 
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 Current researched hydration assessment measures include changes in body mass 
(BM), blood indices (plasma osmolality (Posm), sodium concentration), urine osmolality 
(Uosm), urine specific gravity (USG), urine color (UC) and bioelectrical impedance analysis 
[1, 6, 8]. Urinary measures have demonstrated being more sensitive than other methods 
[6], as well as relatively easy to measure [9], but Posm is better at measuring rapid and 
small changes in hydration status [10]. In search of more practical and noninvasive 
markers of hydration, the relationship between saliva indices (flow rate, osmolality, 
spinability) and dehydration has recently been also investigated [11-13]. If no instrument 
or technical expertise is available, perception of thirst can be taken as an approximation 
of hydration status [1]. For all these methods, specific threshold values indicating levels 
of dehydration have been established [2].  
 Selection of the appropriate hydration assessment method will depend not only on 
the sensitivity and accuracy needed, but also on the technical requirements and cost of the 
method [6]. For instance, since high accuracy and precision are essential for laboratory 
tests, change in body mass would not be a reliable measure of hydration status in that 
setting [14, 15]. On the other hand, for estimation of hydration status of athletes 
exercising in the heat, such practical and inexpensive method is deemed accurate and 
reliable enough [5, 16]. Likewise, markers for hydration status will be different for a 
static and for a dynamic assessment. In a recent study by Cheuvront et al., only Posm was 
recommended for static dehydration assessment, while Posm, Usg and BM were all valid in 
the setting of dynamic hydration assessment [17]. In particular, Usg is the most commonly 
used to assess hydration status in athletes, as long as muscle mass is taking into account 
[18]. For any of these methods, it is important to remember that the reported changes in 
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hydration levels will heavily depend on the initial definition of euhydration [6], and in 
some cases, even individual euhydrated measures are required [13]. Finally, factors that 
may affect the response of specific biomarkers include drug or vitamin consumption, 
food and fluids intake, changes in posture and even how dehydration occurs [18-20]. 
 Despite all the research done in this area, there is still no gold standard for 
measuring hydration status in all situations and populations [1, 5, 9]. Moreover, the 
current values that define hydration levels for the various hydration indices are mostly 
based on expert consensus opinion and not on formal research studies. Only recently, 
researchers are trying to provide reference values for hydration levels based on studies. 
For instance, a  12-day study of 59 healthy males by Armstrong et al attempted a 
statistical approach for providing reference euhydration values and values for extreme 
cases of hydration [21]. Additionally, hydration biomarkers usually measure dehydration 
by observing acute changes during exercise in heat and sports [10, 16, 22, 23], but rarely 
in more “common” condition such as inadequate fluid intake.  
2.1.2 Breath analysis and VOCs 
 Human breath contains nitrogen, oxygen, carbon dioxide, water, inert gases and 
more than 1000 volatile organic compounds (VOCs). These VOCs can be divided into 
different chemical classes including hydrocarbons, alcohols, ketones, aldehydes, esters 
and heterocycles. Unlike NO and other inorganic gases, VOCs are mainly blood-borne, 
and can reflect a normal physiological biochemical process or a pathological condition in 
an individual. Recently, due to technical developments in the separation and 
identification of exhaled substances, the potential of breath analysis as a diagnostic and 
6 
monitoring tool in clinical practice and for environmental exposure assessment has 
greatly increased [24-27]. 
 One of the most interesting applications of breath analysis is the identification of 
molecular biomarkers of disease [28]. Correlations between concentrations of a single or 
a set of VOCs and several clinical conditions, such as lung diseases, oxidative stress, and 
metabolic disorders have been reported in several recent studies [27, 29-31]. The results 
indicate that biomarkers in the breath can detect gastrointestinal and liver diseases [31], 
cancers [32], namely lung cancer [33-35], hepatocellular carcinoma [36], pulmonary 
tuberculosis [37], asthma [38, 39], COPD [39, 40], and type 2 diabetes [41]. In addition, 
identified biomarkers can also be potentially used for the noninvasive measurement of 
circulating variables such as plasma glucose (for diabetes management) [42]. Linear and 
nonlinear multivariate statistical methods have been effective in determining associations 
between biomarkers and disease occurrences [33, 35, 37, 43, 44].  
 Exhaled breath contains both, alveolar and “dead space” air. The latter is the 
ambient air from the upper airway, which dilutes the concentration of the VOCs. 
Alveolar breath comes directly from the lungs and has been in contact with blood. Since 
the concentrations of VOCs in the breath are already very low, then it is recommended to 
collect only the alveolar breath. Another type of contamination in a breath sample comes 
from exogenous compounds in the ambient air, captured during inspiration. A correction 
method to minimize these contaminants is to subtract the substance concentrations in the 
inspired air from the concentrations in the exhaled breath. This difference is called 
“alveolar gradient”, and its sign indicates whether a particular VOC is endogenous or 
exogenous [25, 45]. 
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 Due to their low concentrations (ppmv to pptv), VOCs have to go through 
preconcentration and desorption (usually thermal desorption). Separation of the volatile 
compounds can be done by different methods, being gas chromatography (GC) the most 
common. Likewise, several detection methods can be used in GC to identify the 
compounds, and these include: flame ionization detection (FID), mass spectrometry 
(MS), and ion mobility spectrometry (IMS). Currently, GC/MS is the standard method 
for determining the composition of VOCs in exhaled breath [25, 26, 45]. 
 Breath tests have some advantages over blood or urine tests because they are 
noninvasive, easily repeated and present no risk or discomfort for the patient. 
Furthermore, the composition of breath samples closely reflects the concentration of 
biological substances in the blood, which would eliminate the need for multiple blood 
samples [25, 27]. Recent studies even suggest that breath VOC measurements could 
provide a more consistent measure for investigating underlying physiological function or 
pathology than single blood measurements [28, 46]. Furthermore, the dynamic behavior 
of specific VOCs is also being investigated with the hopes of using them for assessments 
of hemodynamics, pulmonary function and gas exchange patterns [47]. 
 Current limitations in the application of breath analysis in clinical practice 
include: lack of better understanding of the relationships between breath biomarkers and 
pathological conditions, lack of standardization and normalization of procedures for the 
sampling, preparation and analysis of breath samples [25, 27]. 
2.1.3 Summary of Key Research Needs and specific Aims 
 From the literature review, we can extract the following main points: 
1. Dehydration has negative consequences in our overall health 
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2. (Accurate) Assessment of hydration status is difficult 
3. There is no unique golden standard for measuring hydration status 
4. More common methods require collection of bodily fluids 
5. Most methods have poor intra- and inter-personal reproducibility 
6. Breath tests are noninvasive and easily repeated 
 In this chapter, we proposed breath analysis as a new method to measure 
hydration status by analyzing the behavior of VOCs in exhaled breath. We started with an 
initial exploratory research to assess whether hydration status in adults can be measured 
through breath analysis. Analyses were conducted from a sample of over 40 healthy 
subjects, ages 18 to 40. Data mining methods were used to analyze the breath samples 
and classify hydrated vs. dehydrated individuals. 
2.2 Methodology 
2.2.1 Data Collection 
 The collection of breath samples was realized by Dr. Melinda Millard-Stafford 
research group from the Department of Applied Physiology at Georgia Tech. Human 
VOCs from the subjects’ breath, as well as other hydration measures, were collected for 
assessment of hydration status. The de-identified dataset was then provided to us for 
statistical analysis.  
Subjects 
 The subjects were volunteers from the Georgia Institute of Technology campus. 
Forty-six healthy adult subjects, 23 males and 23 females, ages 18-40 years old were 
assessed from July 2010 to March 2011. Subjects were excluded from the study for the 
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following conditions:  diabetes, hypothyroid, hyperthyroid, claustrophobia, current 
weight loss diet, significant weight loss or gain (5% of body weight) in the last three 
months, liver disease such as hepatitis or cirrhosis, pregnancy, or the inability to refrain 
from physical labor or exercise for two consecutive days during the study. Informed 
written consent was obtained prior to initiation of the study as approved by the Georgia 
Tech Institution Review Board. A within-subject research design was used where each 
person acted as their own control.  
Study Protocol 
 The study took place over three consecutive days involving a total of five 
sessions, in which three conditions of hydration status were assessed: 
1) Day 1 – Visit 1: AM free living: Prior to the first visit, subjects were told to fast 
during the 8 hours prior to the visit, although they were allowed to drink water. 
2) Day 1 – Visit 2: PM free living: The hydration period started after this visit. The 
subjects were given instructions for recording their diet and begin the hydration 
protocol (12ml/kg of body weight during the evening and next day along with 
normal fluid/food intake). 
3) Day 2 – Visit 3: Euhydrated 24-hours following PM free living: After collecting 
the breath samples, the subjects were given the dehydration protocol. They 
followed a dry food diet and the only allowable liquids were less than 20ml if 
needed for medication. 
4) Day 3- Visit 4: 16 hours into dehydration. 
5) Day 3 – visit 5: 24 hours into dehydration. 
During each session, breath samples and a variety of other measures were performed. 
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 Breath samples were collected by the subject breathing slowly and deeply five 
times at five-minute intervals into a valved-Teflon sampling bulb (Markes Bio-VOC 
Sampler) containing a Tenax rapid passively sampling device in which the breath VOCs 
were captured. The subjects also completed a questionnaire concerning recent pollutant 
exposures and ingested food that may produce cofounding breath VOCs (the same type 
of questionnaire was previously used in a VOCs breast cancer detection study). The 
sampling device was analyzed by thermal desorption/gas chromatography/mass 
spectrometry (TD/GC/MS) (Markes International Ltd. ULTRA thermal desorber/Thermo 
Trace GC ULTRA/Thermo Trace DSQ mass spectrometer). The VOCs were identified 
from the GC/MS data at an off-campus laboratory by Dr. Charlene Bayer. 
 In addition to the breath samples, the following measures were taken on all visits: 
heart rate (HR), oxygen saturation (O2 sat), blood pressure (BP), body mass (BM), urine 
color (UC), urine specific gravity (USG), Visual Analog Scale of thirst (VAS), and urine 
osmolality (Uosm). O2 sat and HR were measured using a pulse oximeter (Nonin Medical, 
Plymouth, MN).  BP was measured using an automatic blood pressure monitor (OMRON 
Healthcare, Bannockburn, IL). BM was measured on the Pennsylvania 50 Scale (Wiggins 
Scale Co., Atlanta, GA).  UC was measure using a color chart previously described and 
validated[48]. USG was measured with a hand held refractometer (ATAGO). The Osmette 
micro osmometer (Precision Systems, Natick, MA) was used to determine Uosm.  The 
VAS was a 100 mm scale with the anchors being “Not thirsty at all” and “As thirsty as 
possible”. 
 On the first day, body composition was measured to calculate total body water, 
assuming the change in body fat during those 3 days was negligible. Plasma osmolality 
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(Posm) was measured in the last three visits from blood samples taken from the finger. 
Basal metabolic rate was also measured, using a metabolic hood calorimeter, during visits 
1, 3, 4 and 5. In addition to the above measures, subjects completed questionnaires for 
24-hour living on each visit. Subjects also maintained a food log following the afternoon 
visit on the first day. During the dehydration period, the subjects had to collect their urine 
for a 24-hour period. 
2.2.2 Analysis methods  
 The outcome measure was hydration status, a binary variable with values of 1 or 0 
indicating whether a subject was hydrated or dehydrated. The VOCs in each sample 
breath were used to classify the subjects as hydrated or dehydrated. Clinical variables 
such as sex, height, weight, blood pressure were used as potential covariates. Changes in 
body weight, blood and urine osmolality, and urine specific gravity samples were initially 
selected as gold standard biomarkers [5] to monitor the status of hydration/dehydration, 
to compare to the breath measures and to assess sensitivity and accuracy of categorical 
assignments (hydrated, dehydrated).   
 Mass spectrometry data is usually noisy and has more variables than the available 
number of samples (“small n, large p”). In addition, many VOCs for a particular subject 
are not observed (value is 0), which makes the data sparse. Thus, before doing any 
classification analysis, these issues must be addressed. To reduce or filter out the noise, 
some pre-processing of the data is necessary, such as standardization and/or 
normalization techniques. Then, data dimension reduction methods can be applied. 
Only samples from the last 3 visits were included for the analysis of hydration status 
classification. These were: euhydration, 16-hour dehydration and 24-hour dehydration. 
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 The sequence of methods used in the analysis is depicted in Figure 2.1. 
 
 
Figure 2.1 Diagram of the sequence and methods used in the analysis of VOCs 
 
Pre-processing of data 
A. Invalid Data/Missing Values 
Usually, a percentage of the initially identified VOCs will appear in only a few 
observations, and thus, will not be useful for classifying the subjects. We chose 20% as 
the cutout value to eliminate “not useful” VOCs. Thus, if a VOC was present in less than 
20% of the breath samples for each hydration group (i.e., it was present only in 7 or less 
subjects from the euhydration group, and in 7 or less subjects from the 16hr dehydration 
group and in 7 or less subjects from the 24hr dehydration group), then that VOC was 
eliminated.    
B. Standardization 
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The remaining compounds were standardized across subjects to have mean 0 and 
variance 1. 
C. Variable Selection or Filtering 
To determine which VOCs were most useful in the classification of hydrated versus 
dehydrated subjects, we applied to two different variable selection methods: 
1. Normalized difference between two groups: The nonparametric sign test for paired 
samples was used to compare the hydrated vs. the dehydrated group for each VOC. 
The VOCs were ranked and selected based on the absolute values of the statistical 
test. Classifiers were later evaluated for two groups of VOCs, one for p<=0.05 and 
another for p<=0.1 
2. Correlation with hydration profile: An individualized hydration profile (the 
probability of a subject being dehydrated) was built using a logistic regression model 
with some of the hydration measures as predictor variables. The idea was to correlate 
the VOC profile with the hydration profile for each of the VOCs. A compound was 
selected if its absolute correlation value was higher than a specified value. 
Classification methods were evaluated on three groups: VOCs with corr >= 0.15, corr 
>= 0.18 and corr >= 02. 
Subsequent classification algorithms were also used to compare the variable selection 
methods. 
Data classification 
 To distill predictive summaries from the VOC data, Principal Component 
Analysis (PCA) was implemented. The PCA is a procedure that utilizes a linear 
transformation of data to form a set of variables that are uncorrelated. In addition, the 
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totality of these uncorrelated variables (the Principal Components, PCs) preserves the 
variance in the data; however, this variance is compressed in only a few PCs. This linear 
transformation is organized in such a way that the first principal component has the 
highest possible variance (i.e., accounts for as much of the variability in the data as 
possible), and each succeeding component has the largest possible variance, conditionally 
to being uncorrelated with all the preceding components.  
 In real applications, several principal components contain almost all variance and 
can describe the data/problem as accurately as the data itself. Even though PCA is a 
powerful data reduction technique, it is often impossible to attribute any physical 
meaning to any particular PC, since they are linear mixtures of all variables in the 
problem. Thus, application of PCA can be thought of as revealing the internal structure of 
the data in a manner that best accounts for the variance in the data. If a multivariate 
dataset is visualized as a set of coordinates in a high-dimensional data space (one axis per 
variable), PCs can supply the user with a lower-dimensional picture, a “footprint” of this 
multidimensional object when it is viewed from its “most informative viewpoint.” This is 
done by using only a few principal components so that the dimensionality of the 
transformed data is drastically reduced.  
A. Classification algorithm 
 Data was analyzed using MATLAB R2010b (ver. 7.11.0). Since the VOCs are 
likely to be correlated to each other, or at least grouped in clusters according to their 
chemical characteristics, we decided to further apply principal components in order to get 
orthogonal variables. For each subject, a set of PCs at euhydrated and dehydrated points 
was found. Usually, the 1st and 2nd principal components are used as classifying 
15 
descriptors; however, other pairs were also tested, since the discriminatory power may 
not be necessarily connected with the primary principal components [49].  
 As typical in machine learning theory, when we have supervised learning (i.e., 
when we know which PCs are euhydrated and which dehydrated), the PCs are divided 
into two sets: training and validation set. On basis of a training set, a classifier is 
developed and then assessed based on the validation data. Dudoit et al [50] found that 
simple classifiers such as linear discriminant analysis (DLDA) and next neighbor (NN) 
performed better than more sophisticated ones (e.g., classification trees) when applied to 
“large p, small n” problems. In a similar study to classify cancer based on MS spectra, the 
support vector machine (SVM) classifier had the lowest error rate when compared to 
other discrimination methods [51]. Other classification studies with MS data also showed 
the superiority of the SVM, which displayed a robust performance even when the number 
of variables was changed [52]. The SVM takes a set of training PCs, each marked as 
belonging to one of two categories (euhydrated/dehydrated), and builds a model that 
assigns new examples into one category or the other. The resulting SVM model is a 
representation of points in a plane, mapped so that the members of the separate classes 
are divided by a clear gap that is as wide as possible. New examples are then mapped into 
that same space and predicted to belong to a category based on which side of the gap they 
fall on. Unlike linear and quadratic classifiers, the boundaries between the classes could 
be curvilinear and adaptive to the data. These boundaries are established by using the so-
called kernel functions that are sensitive and expressive.  
 The support vector machine classifier was selected for the classification analysis, 
and the VOCs were evaluated on different kernel functions. 
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B. Cross-validation 
 Classifiers generally perform better on training data that are used to construct 
them than the test data. Therefore, to make the estimates of performance measures even 
more reliable, researchers often use a K-fold cross-validation. The original MS (training) 
data set is randomly split into K sets of about equal size. For each 1 ≤ k ≤ K, the kth part 
is regarded as a test and its complement as the training set. The classifier is built using 
this (artificially created) training set and its performance measures are computed using 
the partition that was left out (artificially created test set). When all K classifiers have 
been built and tested, the estimated error rates are averaged across all partitions [53].  
Because of the small number of samples, we selected K=number of subjects. The two 
dominant components served as classifying descriptors. The discriminatory boundaries 
were created using the training sets and correct classification sets assessed by the 
validation sets. This was repeated 20 times. 
Comparison with hydration markers 
 Finally, we compared the performance of our classifier against two well-known 
markers of hydration: urine osmolality (Uosm) and plasma osmolality (Posm) [2, 9, 17] 
2.3 Results 
 The final de-identified dataset consisted of 46 subjects. There were 23 males and 
23 females, with an average age of 23.7 yr., initial average weight of 152 lbs and height 
of 172.4 cm. Men were heavier (169.3 lbs) compared to women (135.1 lbs) and taller by 
12.8 cm. The mean values of the hydration measures for each of the 5 visits are presented 
in Table 2.1.  
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 After some preliminary analysis and input from Dr. Millard-Stafford, five 
variables were excluded from further analysis: Usg, Ucol, 24-hr Uvol, 24-hr Usg and 
thirst rating. The remaining variables were: Sex, Uosm, Posm, TBW and VAS. 
 
Table 2.1 Hydration measures for all 5 visits 
Measure Mean V1 (St. Dev) 
Mean V2 (St. 
Dev) 
Mean V3 (St. 
Dev) 
Mean V4 (St. 
Dev) 
Mean V5 (St. 
Dev) 
Weight (lbs) 152.0 (31.8) 151.9 (31.7) 152.1 (31.9) 150.0 (31.5) 148.9 (31.2) 
Uosm 767.3 (288.9) 736.6 (238.0) 381.7 (176.9) 949.0 (101.2) 1033.5 (96.1) 
Usg 1.021 (0.008) 1.019 (0.006) 1.010 (0.005) 1.027 (0.003) 1.027 (0.003) 
Ucolor 5.1 (1.4) 4.1 (1.4 2.5 (1.4) 6.1 (0.7) 5.9 (0.8) 
Total Body Water 94.2 (20.9) 94.2 (20.9) 94.3(21.1) 92.7 (20.7) 91.9 (20.5) 
Posm -- -- 284 (4.4) 290.6 (5) 292.8 (5.2) 
VAS 3.6 (2) 3.4 (2.2) 2.3 (1.7) 6.4 (1.4) 7.3 (1.8) 
Thirst Rating 3.5 (1.5) 3.7 (1.9) 2.7 (1.6) 6.4 (1.4) 7.5 (1.4) 
24-hr Uvol -- -- -- -- 846.9 (348) 
24-hr Usg -- -- -- -- 1.022 (0.004) 
 
 Breath samples from 10 subjects were found to be contaminated and discarded. 
VOCs for the remaining 36 subjects (22 females and 14 males) were assessed. A total of 
331 VOCs were detected in each subject’s breath sample. Measurements on each subject 
included in the study had two values: VOCs at the point of euhydration and at 24-hour 
dehydration, for a total of 36 pairs of measurements.  
 The first step in the reduction of VOCs eliminated 242 compounds. As mentioned 
in the methods section, we considered “invalid” data those compounds that appeared in 
so few samples that would not be of any value during the classification. A VOC was 
excluded if it appeared in less than 29 subjects, i.e., VOCs that only appear in 7 samples 
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or less for each of the 3 hydration groups. The second step in reducing the number of 
VOCs involved filtering the data in two ways: 
1. Correlating each VOC with a template obtained from the hydration measures 
(hydration profile) 
2. Using a statistical test to identify VOCs that discriminated between hydration groups 
2.3.1 Selection of VOCs using Hydration Profile 
 To obtain the hydration profile for each subject, several logistic regression models 
were evaluated (Table 2.2). Sex was a significant predictor in most models, except when 
Posm was included.  
 
Table 2.2 Logistic Regression Models for hydration measures 
Model Sex Uosm Posm TBW VAS Training Test
1 x x x x 17.353 0.698 0.931 95.7 91.3
2 x x x 24.045 0.675 0.900 94.6 87.0
3 x x 49.174 0.573 0.764 90.2 87.0
4 x x x 51.061 0.565 0.753 88.0 80.4









In addition, only euhydration and 24-hr dehydration were considered in the profile. This 
was due to observing that the values of VOCs were unstable at 16-hr dehydration. Unlike 
the other hydration measures, the VOCs values at 16-hr dehydration did not always fall 
between euhydration and 24-hr dehydration. Figure 2.2 shows the hydration profile for 




Figure 2.2 Hydration Status Profile for the model with Posm and VAS 
 
 All 89 VOCs were correlated with the best three hydration profile models. No 
strong correlations were found between any particular compound and the hydration 
profiles. Most of the compounds had correlations values in the [-0.15, 0.15] range. Of the 
hydration models, we selected the third one (Posm, VAS) as the hydration profile 
template because it presented the highest absolute correlation value (Table 2.3). 
 
Table 2.3 Results of correlations between VOCs and different hydration profiles 
Model Predictors in model Correlation range 
# VOCs 
(corr > 0.2) 
# VOCs 
(corr > 0.18) 
#VOCs (corr 
> 0.15) 
1 Sex, Uosm, TBW, VAS [-0.24, 0.23] 5 8 17 
2 Sex, Uosm, TBW [-0.25, 0.24] 4 6 15 
3 Posm, VAS [-0.28, 0.20] 2 5 13 
 
 The VOCs with the largest absolute correlation values were selected, and several 
classification algorithms were evaluated on different number of VOCs (grouped by their 












Template for hydration profile












correlation values). Principal component analysis was performed on the groups of 
selected VOCs previous to applying the classification algorithms. A linear support vector 
machine classifier was applied to different pairs of principal components. The highest 
correct classification rate was achieved when 13 VOCs (corr > 0.15) were used (Table 
2.4). The following kernel functions were further evaluated on the transformed VOCs: 
Linear, Quadratic, Gaussian radial basis (sigma=1 and 2) and Polynomial. The results 
presented in Table 2.5 show that the linear kernel provided the highest correct 
classification rate. The 1st and the 3rd principal component were the ones that best 
classified the samples (Figure 2.3).  
 
Table 2.4 List of VOCs with abs(corr)>0.15 



























0.2 2 Linear 1,2 0.6503 0.6511 0.6495 
0.18 5 Linear 1,2 0.6965 0.7037 0.6893 
0.15 13 Linear 1, 3 0.7389 0.7242 0.7536 
0.15 13 Quadratic 1,3 0.6831 0.6375 0.7286 
0.15 13 RBF (sigma=1) 6,9 0.6451 0.6393 0.6508 
0.15 13 RBF (sigma=2) 1,3 0.6992 0.6448 0.7536 
0.15 13 Polynomial (order=3) 1,3 0.6524 0.5213 0.7835 
Highlighted row is the kernel function with the highest correct classification rate 
 
 
Figure 2.3 1st and 3rd Principal Components for the correlated VOCs 
 
 The performance of the classifier was evaluated using the K-fold cross-validation 
method. The classifier was trained and evaluated K=10 times, and this was further 
repeated 30 times. The estimated error rates were averaged across all partitions and 
repetitions. In this case, the specificity value indicated the rate of dehydrated subjects 





























correctly classified as being dehydrated. In Figure 2.4, euhydrated and dehydrated 
subjects are indicated by 0 and 1, respectively. 
 
Figure 2.4 Classification with linear Support Vector Machine classifier 
 
2.3.2 Classification of VOCs selected using statistical tests 
 Another method to reduce the number of VOCs used for classification, without 
using hydration measures, consists in performing a preliminary selection of VOCs based 
on the ratio of their between-group to within-group sums of squares (BW ratio). The 
larger the ratio, the more likely the compound will be relevant to the classification. Since 
this was a repeated measures design, we used a nonlinear test for paired samples to 
compare between hydration groups (euhydration vs. 24hr dehydration). The VOCs with 
the largest BW ratios were selected and used in the classifiers.  Before applying the 
classifier, the selected VOCs were transformed into their principal components.  
































 Previously, while building the hydration profile (refer to Table 2.2), we found that 
gender was significant in almost all the models. Thus, we decided to also include it in the 
classifier and the variable gender was then added to the selected VOCs when calculating 
the PCs.  The classifiers were evaluated for two groups of VOCs using the following 
cutout values, p=0.05 and p=0.1. The classified compounds are listed in Table 2.6. The 
first 4 compounds have p <= 0.05. When all 9 VOCs were used, the 6th and the 9th PCs 
were selected for the classification. For the group of 4 VOCs, the 2nd and the 3rd PCs 
obtained the highest classification rates. The results in Table 2.7 indicate that the linear 
SVM classifier applied to the group of 4 VOCs generated the highest correct 
classification rate. Also, the results from adding the gender vector are slightly higher than 
when not using it. 
 
Table 2.6 Selected VOCs with p <= 0.1 





toluene  0.0501 
(Z)-1-(methylthio)-1-propene 0.0574 
1-nonene 0.0923 







Table 2.7 Results for evaluating different SVM classifiers on the transformed VOCs 
PC Kernel function Correct Rate Sensitivity Specificity 
p <= 0.1 (9 VOCs) 
6,9 Linear 0.6404 0.6131 0.6678 
p <= 0.05 (4 VOCs) 
2,3* Linear 0.6646 0.5523 0.7768 
2,3 Linear 0.6671 0.5567 0.7776 
2,3 Quadratic 0.6061 0.4988 0.7135 
2,3 RBF (sigma=2) 0.6523 0.5567 0.7478 
2,3 RBF (sigma=1) 0.6211 0.5258 0.7165 
2,3 Polynomial 0.5933 0.4389 0.7478 
* In this case, the female vector was not added to the 4 VOCs 
 
The 2nd and the 3rd principal component were the ones that best classified the samples 
(Figure 2.5) 
 
Figure 2.5 VOCs with p<=0.05 represented by their 2nd and 3rd PCs 
 
 The performance of the classifier was evaluated using the K-fold cross-validation 
method. The classifier was trained and evaluated K=10 times, and this was further 
repeated 30 times. The estimated error rates were averaged across all partitions and 



























repetitions. In this case, the specificity value indicated the rate of dehydrated subjects 
correctly classified as being dehydrated. In Figure 2.6, euhydrated and dehydrated 
subjects are indicated by 0 and 1, respectively. 
 
  
Figure 2.6 Results from linear SVM classifier using the 2nd and 3rd PC 
 
2.3.3 Comparison of the breath classifier with other hydration measures 
 The performance of the breath classifier was compared to two well known 
hydration measures: Uosm and Posm. Several logistic regression models to predict 
hydration and 24hr dehydration were built. The classification rates of all the models are 
presented in (Table 2.8). The best classification rate is achieved by Uosm, which correctly 
predicted almost all subjects (99.3%). Posm only achieved 81.2%, however, when VAS 
was added to the model, the classification rate was 92.8%. 
 


































Correct Dehydrated Hydrated 
HydStatus Dehydrated 91 1 98.9 
Hydrated 0 46 100.0 





Correct Dehydrated Hydrated 
HydStatus Dehydrated 79 13 85.9 
Hydrated 13 33 71.7 
Overall Percentage     81.2 




Correct Dehydrated Hydrated 
HydStatus Dehydrated 86 6 93.5 
Hydrated 13 33 71.7 
Overall Percentage     86.2 




Correct Dehydrated Hydrated 
HydStatus Dehydrated 85 7 92.4 
Hydrated 10 36 78.3 
Overall Percentage     87.7 




Correct Dehydrated Hydrated 
HydStatus Dehydrated 88 4 95.7 
Hydrated 6 40 87.0 
Overall Percentage     92.8 
 




The correct classification rate for breath analysis, when selecting VOCs with the 
hydration profile, was 73.89%, which was lower than any of the rates in Table 2.8.  
 From these results, it is clear that breath analysis is still not a strong marker of 
hydration status, and other more established hydration markers have superior 
performance.  
 A few limitations in this study were: 
• In this type of study design, it is difficult to obtain a large enough representative 
sample of the overall population. It usually represents only a group of the total 
population (in this case, healthy young people ages 18 to 40). 
• Although the initial number of subjects is 46, the number of available breath samples 
was reduced by 10 due to contamination of the samples or malfunction of the 
equipment. 
• Mass spectrometry (MS) has the potential to identify more sensitive biomarkers of a 
health condition than current ones. However, the process is very sensitive to changes 
in the protocol of sample and spectra collection [53]. The MS data provided to us was 
already preprocessed; therefore, our results were restricted to the quality of the 
preprocessing steps. 
• During the 8 months of data collection, two different MS equipment were used for the 
analysis of the samples. The machines did not identify the same set of VOCs for the 




  Exhaled breath samples from 36 subjects were evaluated. Two measurements 
from each subject were analyzed: euhydration and 24-hour dehydration. Data dimension 
and classification methods were applied to the 331 VOCs found in each breath sample. 
When the sign test was used to select relevant VOCs, the highest correct classification 
rate achieved was 66.71%. When VOCs were selected by correlating them to the 
hydration profile, the classification rate was 73.89%. Although these results are better 
than flipping a coin (50%), they are still inferior when compared to other used marker of 
hydration such as Uosm and Posm.  
 Breath analysis presents large variability in the number and concentration of 
VOCs [32], thus, until a true criterion in hydration is clearly established for a single point 
in time measure (as compared to following changes from known euhydration to 
dehydration), many more samples would need to be obtained (with substantial investment 
in the technology). Additionally, a better understanding of the specific VOCs involved in 
the physiological changes due to dehydration is very much required. For instance, in our 
study, most of the VOCs selected for classification were compounds to which subjects 
may have been exposed from the environment - such as limonene (emitted from building 
materials), 2-butoxyethanol (found in many cleaning products), decane, heptacosane, 
heptacosane, dodecane (alkaids found in combustibles), and triacetin (found in cosmetics 
and personal care products), and their role in the dehydration process is not clear. 
 Although our results did not provide an improvement on other hydration 
measures, application of breath analysis to areas such as classification of diseases has 
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been more successful [32, 42, 44]. In the topic of hydration classification, future research 
could include: 
• Evaluation of the validity of using fingerstick Posm as a less invasive measure 
(compared to venipuncture) of hydration status.  
• Analysis of the VOC signature of the other dehydration group: 16-hours dehydrated 
and evaluate classification models to discriminate against the euhydrated and the 24hr 
dehydrated groups. 
• Identify from the literature and field experts, the VOCs that can potentially describe 




CHAPTER 3 : IMPACT OF EMR ON MEDICAL ERRORS AND 
ADVERSE DRUG EVENTS 
 
3.1 Literature Review 
3.1.1 Patient safety, medication errors and adverse drug events 
 According to the 2007 report Preventing Medication Errors by the Institute of 
Medicine, medication errors are the most common medical errors, and the report 
“estimated that on average, a hospital patient is subject to at least one medication error 
per day, with considerable variation in error rates across facilities” [54]. These findings 
are further supported by other studies identifying the high incidence of medication errors 
within healthcare facilities [55, 56]. Although not all errors lead to injury or death, the 
report found that medication errors injure at least 1.5 million people per year. Medical 
errors can happen at different stages in the medication process: prescribing, filling, 
dispensing, or administering; however, most of them occur during prescribing [56, 57]. 
Therefore, the implementation and utilization of an electronic prescribing system would 
greatly help reduce the frequency of medication errors [58]. 
 Using the definition of the National Coordinating Council for Medication Error 
Reporting and Prevention (NCC MERP), a medication error is “any preventable event 
that may cause or lead to inappropriate medication use or patient harm while the 
medication is in the control of the health care professional, patient, or consumer. Such 
events may be related to professional practice, health care products, procedures, and 
systems, including prescribing; order communication; product labeling, packaging, and 
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nomenclature; compounding; dispensing; distribution; administration; education; 
monitoring; and use”. Similarly, and adverse drug event (ADE) is defined as “an injury 
resulting from medical intervention related to a drug” [56]. ADEs may or may not result 
from medication errors, and studies show that few ADEs actually result from them [56], 
occurring  most often during the ordering stage [59]. As in the case with medication 
errors, health information technologies (HITs) such as computerized physician order 
entry (CPOE) systems can help prevent many of these ADEs. A preventable ADE is an 
injury that is the result of an error at any stage in the medication use. A non-preventable 
ADE, a.k.a., adverse drug reaction (ADR), is an injury due to a medication, but in this 










Figure 3.1 Relationship between medication errors and adverse drug events [60] 
 
 There is variability in the number of medication errors and ADEs reported by 
healthcare organizations, mainly due to the lack of standardization in the definitions and 









have been identified in the rate of ADEs [62], as well as in the rate of reported 
medication errors [63]. Due to the complexity of patient cases and medications in the 
intensive care units (ICUs), medical errors and adverse events have been reportedly 
higher than in general care units [63]. There are also differences regarding patient 
populations. Children are at greater risk than adults for medication errors [64]. Children 
in particular are more susceptible to serious medication errors due to weight-based 
dosing, off-label drug usage and preparation, limited ability to withstand a dosing error 
and a limited ability to communicate with healthcare professionals when an error might 
occur or has occurred [65, 66]. In a study in two academic pediatric hospitals, it was 
found that errors occurred at a rate of 5.7 errors per 100 orders, with 79% of these errors 
occurring at the ordering stage [66]. Errors with potential to cause harm were three times 
more likely to occur in pediatric inpatients compared with adults [56, 66]. The risk for 
adverse events is even higher in pediatric ICUs [67]. Other factors that put patients at 
higher risk for ADEs and medication errors are increased drug exposure and hospital stay 
[68, 69]. 
3.1.2 HIT and patient safety 
 One of the recommendations of the 2007 IOM report to improve patient safety 
was for healthcare organizations to have electronic prescribing in place by 2010 [54].  
A recent national survey on US hospitals from 2011 found that 26.6% of hospitals had at 
least a “basic” electronic health record (EHR) system, while 8.7% had a “comprehensive” 
system. From a previously developed definition, a basic system has the following 
deployed technologies in at least one hospital unit: computerized systems for patient 
demographics, physician notes, nursing assessments, patient problem lists, laboratory and 
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radiologic reports, diagnostic test results, and order entry for medications. A 
comprehensive EHR system must include all of the functions that a basic system can 
perform and fourteen additional functions deployed in all major hospital units [70].  
 Since most medication errors occur during the ordering and prescribing process, 
electronic prescribing has the potential to greatly reduce the risk of medication errors and 
ADEs. Electronic prescribing is provided by Computerized Physician Order Entry 
(CPOE) systems, which refers to computer-based systems that automate the medication 
ordering process [71, 72]. CPOE systems can ensure legible and complete orders and 
assist the physician during ordering by providing evidence-based decision support tools 
[73] such as checking drug-drug interactions, drug allergies, or drug-laboratory 
interactions [74] . For example, the system can check for age specific dosing regimens 
and doses above or below the usual range, display alerts to the user if the current 
laboratory values indicate that the drug would be inappropriate for a certain patient. In 
addition, data collected from such systems can be used to automatically detect signals 
associated with an adverse reaction [75]. Although the evidence regarding the 
effectiveness of CPOE to reduce prescribing errors is still modest [76], several studies 
have demonstrated that CPOE systems help decrease the frequency of errors and ADEs in 
both the adult and the pediatric settings [77-81], as long as they also include the adequate 
decision support mechanisms [82, 83]. CPOE would be even more effective if it were 
connected to other computerized system [84] that would prevent the remaining routes for 
errors (e.g., during the medication administration process) [85]. An inpatient EHR with 
CPOE in a teaching hospital decreased medication errors per 1000 hospital days from 
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17.9 to 15.4 and the percentage of medication events that were medication errors from 
66.5% to 55.2% [86].  
 Transcription errors can be reduced using electronic medication administration 
record (eMAR) systems. The main functions of these systems are to organize medication 
administration schedules and ensure timely medication administration [87]. In a study by 
Mekhjian, CPOE combined with eMAR completely eliminated physician and nursing 
transcription errors [88]. 
 Other systems that can reduce medication errors and ADEs are pharmacy-based 
computer systems and smart pumps. Although their usefulness might be limited to 
interventions after an order has been written, pharmacy-based computer systems help 
prevent fundamental ADEs such as drug-allergy and drug-drug interactions. Smart pump 
technologies provide clinicians with safeguards for proper dosing; however, to detect and 
avoid medication errors, smart pumps have to be properly implemented and clinicians 
have to be properly trained to use them [89]. 
 The implementation strategy of an IT system is also an important of preventing 
medication errors [74]. For instance, a meta-analysis study that evaluated the 
effectiveness of CPOE systems found that its implementation process may be associated 
with adverse outcomes and can decide the success or failure of the system [90]. A recent 
study review highlighted the “human element” as a critical component to the 
implementation of HITs, finding a strong association between provider satisfaction and 
negative outcomes [91]. It is worth mentioning that despite the numerous studies on the 
positive impact of HIT, a few of them have also described the potential for new kind of 
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medication errors, not only because computer interfaces but also because of human errors 
[92, 93].   
3.1.3 Analysis of medication errors and adverse drug events 
 The outcome of interest when evaluating ADES and medication errors is usually 
some type of count data, e.g., frequency, incidence, or rate of events. Most studies found 
in the literature that analyzed medication errors and/or ADEs in hospitals used univariate 
analysis such as t-test, one-way ANOVA or χ2 test [72, 94]. These techniques are valid to 
evaluate associations of independent variables to outcomes variables; however they don’t 
account for the effect of covariates. A few studies used logistic regression to identify the 
risk factors associated to ADEs and medication errors [63, 95-98], but these models only 
predicted the absence or presence of the event.  
Methods for modeling count data 
 There are several methods that can used to model count data. The most commonly 
used method to model count data is the Poisson regression [99]. If the data presents 
overdispersion or a high frequency of zero counts [100], it would violate the Poisson 
assumption of variance and mean equality. In those cases, applying a Poisson model 
would underestimate the observed dispersion, resulting in improper estimates of the 
standard errors and increasing the type I error. One approach for this problem is to use 
the negative binomial, a more flexible model than the Poisson, which allows the variance 
to be greater than the mean. An alternative to the negative binomial, for cases when the 
data presents a large frequency of extra-zeros, is to use either the zero-inflated or hurdle 
models [101, 102]. The options are the zero-inflated Poisson (ZIP), zero-inflated negative 
binomial (ZINB), and similarly, the hurdle Poisson and the hurdle negative binomial. 
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Zero-inflated models assume that the population consists of two different groups, with 
the zeros coming from both of them. A description of the aforementioned models 
follows: 
a. Poisson regression is a form of a generalized model in which the response variable yi 
is modeled as having a Poisson distribution, and the explanatory variables  (vector 
of linearly independent regressors) determine the mean of the response variable, i.e., 
µi. The Poisson regression model is defined as follows [103]: 
Density function of yi given xi:    
|
!
, 0, 1, 2, …         (1) 
To ensure that µi > 0, the mean parameter is parameterized using the log link 
function: 
exp             (2) 
b. Negative Binomial: The most common form of the negative binomial model is the 





,     α 0,     y 0,1,2, …  (3) 
When α = 0, this reduces to Poisson. 
c. Zero-inflated count models assume that the population consists of two distinct groups, 
with zero counts generated from both groups. The ZIP model for the response yi can 
be represented as [101]: 
 yi ~ 0     with probability  φ          (4a) 
 yi ~ Poisson(µi)  with probability 1 φ     i 1, … , n      (4b) 
so that: 
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 Pr y 0 φ 1 φ e µ ,         (5a) 
 Pr y r 1 φ
µ µ
!
 ,              r 0,       (5b) 
where   
 logit φ γ w            (6) 
and 
 log µ β x             (7) 
A characteristic of this model is that the effects of the covariates can be examined 
simultaneously in both components. The covariates are not necessarily the same for 
both components, and two different set of covariate vectors are allowed in these 
models. For the ZINB, the Poisson distribution is replaced by the negative binomial 
in the ZIP model. 
d. The Hurdle model can also be interpreted as a two-part model, with the first part 
being a binary outcome model, and the second part a truncated count model. This is 
useful for the cases in which the data may come from two sources, thus partitioning 
the population into subpopulations [103]. If the hurdle is set at zero, it would result in 
a group with zero elements, and a second one with positive counts. This model is 
defined as follows: 
Pr y 0 f 0            (8a) 
Pr y j f y φf y ,                 j 0   (8b) 
where φ 1 f 0 / 1 f 0  can be interpreted as the probability of crossing 
the hurdle.  
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Evaluation and selection of count data models 
 The models described above can be compared and evaluated in different ways: 
- To identify overdispersion in the data, several tests can be applied. An indication of 
the magnitude of overdispersion can be obtained by simply comparing the sample 
mean and sample variance of the dependent variable. Application of the Poisson 
regression decreases some of the conditional variance of the dependent variable. 
However, if the sample variance is more than twice the sample mean, then the data is 
likely to remain overdispersed after the inclusion of regressors [76].  
- Comparison of nested models such as Poisson vs. Negative Binomial or ZIP vs. ZINB 
can be compared using likelihood ratio, the Wald and the Score tests.  
- Similarly, methods to compare nonnested models (Poisson vs. ZIP, NB vs. ZINB) 
include the Akaike Information Criteria (AIC), the Bayesian Information Criteria 
(BIC) and the Vuong test. 
2 log L 2 ,  where p is the number of parameters   (9) 
2 log log , where p and n are, respectively, the number  
of parameters and observations              (10) 
- Finally, goodness-of-fit tests can also be used to select models based on how well the 
predicted values compare with the observed ones. 
3.1.4 Summary of Key Research Needs and Specific Aims 
 From the literature review, we extracted the following points: 
1. Most medical errors and adverse drug events occur during the prescription and 
ordering processes.  
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2. Because of 1), healthcare information technologies such as eMAR, CPOE and EMR 
have the potential to greatly reduce the number of medical errors and adverse drug 
events.  
3. Although implementation of HIT systems is growing, only a small percentage of 
hospitals have implemented “comprehensive” electronic health systems (8.7% in the 
2011 AHA survey). 
4. The mere deployment of information technology systems in a healthcare organization 
does not guarantee the improvement of patient safety and healthcare quality.  
5. New types of errors are bound to appear with the implementation of HIT systems. 
6. Rates of medication errors and adverse events are not the same across a healthcare 
organization, so there is a need to evaluate them according to those differences. 
7. Healthcare outcome measures like medication errors and ADEs are count data, so 
linear regression methods are not appropriate. Likewise, because of the high number 
of zero events, simple Poisson models might not always be a good fit. 
 
 This chapter attempts to contribute to the knowledge base of healthcare in two 
ways. First, it increases the knowledge base of implementing HITs by developing a better 
understanding of the impact of an incremental EMR implementation on patient safety, 
measured by the change in the rate of medical errors and adverse drug events. We 
focused on the pediatric inpatient setting because the medication administration process 
in children is more complicated [66], and thus, the occurrence of a medication error is 
more critical. Additionally, it was also of interest to examine the impact of HITs on 
reducing the differences between hospital types and areas. 
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 The second main objective of this chapter is to identify and recommend the most 
adequate model for the analysis of count data in healthcare, in particular of the 
occurrence of medication errors, which usually presents a high number of zeros. The 
occurrence of events or incidents in healthcare settings exhibits some particular 
characteristics that must be considered when selecting a distribution that will fit the data. 
For those cases, logistic regression models do not suffice. In this study, we discuss the 
application and evaluation of six alternative nonlinear regression models to describe the 
frequency of medication errors and adverse events.  
3.2 Methodology 
 This chapter examined the impact of an electronic medical record system 
implementation on the rate of medical errors and ADEs in two campuses of a pediatric 
healthcare system. Details regarding the study context, population and (a priori) data 
collection are described below, as well as the statistical analysis methods used. 
3.2.1 Study Context 
 This was a retrospective longitudinal study of patients at two inpatient facilities, 
one academic and one community-based, in a pediatric health care system. Children's 
Healthcare of Atlanta (CHOA) implemented a series of electronic medical record (EMR) 
components over several years to improve patient safety and quality as well as increase 
efficiency of all operations.  The system implementation occurred over four years (2004-
2008). The implementation stages that were included in this study, in order of 
implementation are: 
1. Inpatient Pharmacy System (Jan 2005) 
2. Electronic Medication Administration Record and Clerk Order Entry (Nov 2005) 
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3. Nursing & Ancillary Documentation (May 2007) 
4. Physician Documentation (Aug 2007) 
5. Computerized Provider Order Entry System (June 2008) 
 This phased implementation approach allowed for the introduction and mastery of 
each EMR component separately, and for the separate analysis and reporting of each 
component and its contribution to improving patient safety and quality of care. 
 
 
Figure 3.2: EMR Implementation Stages 
 
Data Collection 
 Data collection for this study happened at six periods of time: the first, baseline, 
two months before the implementation of the first EMR component (EPIC Rx) and then, 
6 to 8 months after the implementation of each additional EMR functionality. Since we 
were particularly interested in the impact of the EMR components involving the 
physicians, a baseline measurement was also taken before their implementation (T3). 
 A randomly selected list of patients was generated for each phase of the data 
collection.  Patients were eligible for inclusion if they belong to either the general or the 
intensive care area, and had a minimum of 2 day admission.  
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Table 3.1 Data collection periods 
Time Period Phase 
T0 (Nov 04 – Feb 05) Prior to EMR implementation 
T1 (Apr 05 – Jun 05) Post EPIC Pharmacy System (EpicRX) 
T2 (May 06 – Jun 06) Post eMAR / Smart Pumps 
T3 (Feb 07 – Mar 07) Baseline measure Pre CPOE / Safety initiatives 
T4 (Sep 07 – Nov 07) Post Nursing & Physician Documentation 
T5 (Sep 08 – Oct 08) Post CPOE 
 
Identification and classification of medication errors and adverse drug events 
 Retrospective reviews of the medical charts were conducted by researchers from 
the pharmacy department at CHOA. A trigger chart tool was used to assist in identifying 
possible medication errors and adverse drug events. This method was selected because 
several studies have demonstrated that it is more effective than voluntarily reporting of 
incidents to identify ADEs in pediatric hospitals [104, 105].  The tool was created from 
the Institute for Healthcare Improvement (IHI) trigger tool for measuring adverse drug 
events and a list from the Institute of Safe Medication Practice (ISMP).  It collected 
baseline demographics such as date of birth, admission, discharge and total number of 
doses a patient received during a maximum of 14 days.  The data collection tool directed 
the reviewer to five specific parts of the chart: 1) discharge summary, 2) orders, 3) 
anesthesia records, 4) medication administration record and 5) ancillary nursing notes.  A 
list of common antidotes and medications used for treating adverse drug events were 
evaluated in the trigger tool. If a potential error or adverse event was identified, a brief 
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description of the incident was documented. The reviewer would then score the incident 
using a list of harm categories (see Table 3.2) based on the system for classifying the 
medication errors by the National Coordinating Council for Medication Error Reporting 
and Prevention (NCC MERP). The data collection sheets were transcribed into an access 
database. The process followed for the chart review is explained in further detail in 
Rozich et al [106]. 
 
Table 3.2 Harm Categories based on the NCC MERP classification of errors 
Category Description 
A Circumstances or events that have the capacity to cause error 
B An error occurred but the error did not reach the patient (An "error of omission" does reach the patient) 
C An error occurred that reached the patient but did not cause patient harm 
D An error occurred that reached the patient and required monitoring to confirm that it resulted in no harm to the patient and/or required intervention to preclude harm 
E An error occurred that may have contributed to or resulted in temporary harm to the patient and required intervention 
F An error occurred that may have contributed to or resulted in temporary harm to the patient and required initial or prolonged hospitalization 
G An error occurred that may have contributed to or resulted in permanent patient harm 
H An error occurred that required intervention necessary to sustain life 
I An error occurred that may have contributed to or resulted in the patient’s death 
 
Data Description 
 The final dataset provided by the CHOA researchers did not include any patient 
identifiers (a HIPAA waiver was approved in the GT IRB protocol). A total of 2278 
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triggers were identified (including T0: No triggers found). The data included the 
following variables:  
• Patient Number: It associates the trigger to an individual patient 
• Time period: One of the six time periods of the data collection 
• Patient group: There were 4 groups, a combination of the two areas (General or 
Intensive Care) and two hospitals (Egleston or Scottish Rite) 
• Type of event: According to the trigger review, there were three options: ‘No 
event’, ‘ADE’ or ‘Error’ 
• Harm category: From A to I 
• Doses per day (for a 14-day period) 
• Date of birth 
• Date of admission 
• Date of discharge 
3.2.2 Data Analysis 
 The following additional variables were calculated from the collected data: 
• Age: This is the patient age at time of admission 
• Length of Stay: Number of days between date of admission and discharge 
• Reviewed Days: This is equal to Length of Stay if less than 14, otherwise it is 14 
• Number of errors and ADEs for each harm category (calculated by patient) 
• Total number of doses: The total number of doses a patient was given during the 
reviewed days. This variable was used as the exposure variable, based on the 
assumption that the probability of an error or ADE is the same for each dose 
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• Rate of med errors and ADEs: That is the number of medication errors or ADEs 
per dose. 
 Length of stay and age were transformed into categorical variables. Length of stay 
was grouped into two categories: 
• L1: 1 to 7 days 
• L2: 8 or more days 
 The following pediatric age group classification was used: 
• Neonates: 0 to 27 days 
• Infants and toddlers: 28 days to 23 months 
• Children: 2 to 11 years 
• Adolescents: 12 to 18 years 
Outcome measures 
 In addition to modeling the number of all ADES and medication errors, the 
pharmacists at CHOA were also interested in examining the events that reached the 
patient and had potential for harm, i.e., categories D and above. Therefore, the following 
outcome measures were examined: 
1. Rate of all medication errors 
2. Rate of all ADEs 
3. Rate of medication errors category D or higher 
4. Rate of ADEs category D or higher 
 For each time period and patient subgroup (by hospital and by care area), the rates 
of medication errors and ADEs per 1000 doses were calculated and trends across time 
periods examined.  
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Potential initial predictors 
 Based on the literature review, potential associations between each outcome 
measure and the following variables were assessed:  
1. Time period: Six times periods, from T0 to T6 
2. Hospital: Two hospitals (EG or SR) 
3. Care area: General care (GCA) or Intensive care (ICU)  
4. Age: The age of the patient at admission 
Data models 
The following nonlinear models were constructed for each outcome measure: 
1. Poisson model (P) 
2. Negative Binomial (NB) 
3. Hurdle Poisson (HP) 
4. Hurdle Negative Binomial (HNB) 
5. Zero-inflated Poisson (ZIP) 
6. Zero-inflated Negative Binomial (ZINB) 
 Nested models (e.g., Poisson vs. Negative Binomial) were compared using the 
Likelihood ratio test. Nonnested models (e.g., Poisson vs. Zero-inflated Poisson) were 
compared using the Vuong test. All models were compared using the Akaike Information 
Criteria (AIC). The statistical modeling was performed in version 2.9.2 of R: A Language 




3.3 Results and Discussion 
 A total of 959 patients were randomized and evaluated for possible ADEs and 
medication errors using the trigger tool.  Approximately 160 patient charts were 
examined for each time period (except at baseline): forty patients each from GCA and 
ICU from both campuses were reviewed. The final dataset had 937 inpatient charts. 
Charts were excluded for the following reasons: 
• 10 charts had missing data: medication data missing or incomplete (7), labs data 
missing (1), date of birth missing (1), time period missing (1)  
• 8 charts had 0 dose count 
• 3 charts had length of stay < 2 days 
• 1 chart was a duplicate 
Of the 937 examined patient charts, 80 (8.5%) presented at least one medication error, 
and 223 (23.8%) had at least one adverse drug event (Table 3.3). The mean number of 
medication errors was 0.1 and of ADEs was 0.34. 
 
Table 3.3 Frequency distribution of medication errors and ADEs 
Number of 
errors Frequency Percent  
Number of 
ADEs Frequency Percent 
0 857 91.5% 0 714 76.2% 
1 70 7.5% 1 154 16.4% 
2 7 0.7% 2 43 4.6% 
3 2 0.2% 3 22 2.3% 
4 1 0.1% 4 4 0.4% 
 
 Table 3.4 presents the descriptive statistics for the independent variables. The 
distribution of patients and the percentage of patients that experienced one or more 
incidents are presented for each category of the variables.  
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Table 3.4 Descriptive statistics for independent variables 
Variable   Number of patients (%) 
% of patients with 1 or 
more med errors   
% of patients with 1 
or more ADEs 
Age Neonates 129 (13.8) 5.4   21.7 
  Infants & toddlers 280 (29.9) 7.1   20.4 
  Children 333 (35.5) 9.6   22.8 
  Adolescents 171 (18.2) 9.4   29.2 
  Adults 24 (2.6) 20.8   50.0 
Time T0 88 (9.4) 17.0   12.5 
  T1 174 (18.6) 9.2   14.4 
  T2 160 (17.1) 10.6   28.8 
  T3 163 (17.4) 14.1   30.7 
  T4 177 (18.9) 3.4   29.4 
  T5 175 (18.7) 1.7   22.3 
Hospital EG 459 (49.0) 7.2   29.2 
  SR 478 (51.0) 9.8   18.6 
Area GCA 440 (47.0) 5.9   19.8 
  ICU 497 (53.0) 10.9   27.4 
LOS2 1 to 7 days 653 (69.7) 6.9   15.8 
  More than 7 days 284 (30.3) 12.3   42.3 
 
 The average length of stay was 11.6 days, ranging from 2 to 263 days. Most of the 
patients in the study were hospitalized less than a week. The overall mean length of stay 
did not vary significantly over time, except during T4 and T5. The community-based 
hospital (SR) had equal or higher overall LOS than the academic-based one, except 
during T5. The LOS in the ICUs was always higher than in the GCA, and that difference 
was maintained at every time period. 
Table 3.5 Average length of stay in days by hospital and area over time 
  T0 T1 T2 T3 T4 T5 Total 
EG 6.8 8.4 7.2 9.4 13.6 19.6 11.4 
GCA 3.3 2.7 4.6 4.8 5.6 6.4 4.7 
ICU 10.6 13.8 9.6 13.8 20.0 31.5 17.6 
SR 9.7 10.4 6.8 10.2 17.2 15.0 11.8 
GCA 3.6 3.0 2.8 3.7 6.0 4.1 3.9 
ICU 13.0 18.0 10.6 15.4 27.1 23.7 18.5 
Total 8.4 9.4 7.0 9.8 15.4 17.4 11.6 
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 About four fifths of ADEs (78%) belonged to harm categories D and above, while 
only two fifths of medication errors (39%) belonged to the same categories 
The rates of medication errors and ADEs seen from Figure 3.3 to Figure 3.6 were 
calculated using the values in Table 3.6. 
 
Table 3.6 Distribution of medication errors and ADEs by patient subgroup 
Time 
Period Hospital Area Charts Total Doses All Errors Errors D+ All ADEs ADEs D+
Total 937 86323 94 37 322 251 
T0 EG GCA 20 603 1 1 7 7 
    ICU 19 1744 4 2 2 2 
  SR GCA 17 458 4 0 5 5 
    ICU 32 3020 8 1 4 3 
T1 EG GCA 41 1182 2 0 9 9 
    ICU 43 4563 2 2 14 14 
  SR GCA 46 905 2 0 3 2 
    ICU 44 6214 12 1 10 9 
T2 EG GCA 39 2351 6 1 14 7 
    ICU 40 4245 4 3 15 6 
  SR GCA 40 1288 4 0 10 8 
    ICU 41 3874 5 1 24 18 
T3 EG GCA 40 3431 10 6 23 11 
    ICU 42 5771 6 2 36 26 
  SR GCA 36 924 0 0 12 7 
    ICU 45 6326 15 12 19 17 
T4 EG GCA 38 3937 2 1 17 14 
    ICU 48 10022 1 1 25 24 
  SR GCA 43 1534 1 0 7 6 
    ICU 48 7273 2 0 15 13 
T5 EG GCA 42 1790 0 0 10 10 
    ICU 47 8016 1 1 22 15 
  SR GCA 38 1661 0 0 7 6 
    ICU 48 5191 2 2 12 12 
 
 The rate of medication errors showed an overall potential trend downwards across 
time (Figure 3.3). Overall error rates dropped to almost zero at T4 and T5. The error rate 
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for high severity categories (D and above) was initially quite low and remained low 
throughout the study period, except for an increase in the error rates of the community-
based hospital during T3. The first reduction in the rate of medication errors occurred 
after the implementation of EpicRx, and the second reduction was after implementing the 
physician documentation function. Initial differences between hospitals disappeared over 
time. 
 Surprisingly, the error rates for the ICUs were lower than for GCAs, except 
during T3, when the rate for the GCA in SR was 0. The largest reduction in medication 
error rates over time was observed in the general care areas for both hospitals, in 
particular for the community-based one (Figure 3.4). 
 
 






























Figure 3.4 Medication error rates by hospital and care area 
 
 The rate of ADEs was higher than the rate of medication errors. ADE rates, since 
they include known, expected medication side effects, were more variable across the 
study period. The most variability occurred during T2 and T3. The rate of overall ADEs 
did not decrease at the end of the EMR implementation with respect to baseline, and it 
actually increased during T2 and T3. Initial differences in the rate of ADEs between 
hospitals disappeared by T5 (Figure 3.5).  
 At the beginning of the study, the rate of ADEs in the GCAs was much higher 
than in the ICUs. The rate of ADEs in the GCAs decreased drastically from T0 to T1. 
After T1, the rate of ADEs either remained the same or increased, except for the GCA at 
EG, where we observed a slight decreasing trend in the rate of ADEs.  The initial 
differences between care units decreased by T4 and ADE rates remained almost the same 





























Figure 3.5 Rate of ADEs (All and D+) by hospital type 
 
 




















































 During the implementation of the EMR, CHOA initiated other projects in addition 
to EMR to reduce ADEs and medication errors.  During August 2005 (between T1 and 
T2), smart pump technology for syringes was implemented to prevent medication errors 
at the bedside by catching any miskeys and/or pump programming errors. Also, in 
summer 2006 (between T2 and T3), the pharmacy completed a Six Sigma project 
targeting a reduction in medication errors in preparation and dispensing medications.  
The phased EMR implementation and these other initiatives contributed to the changes in 
medication error rates and ADEs observed in this study. 
3.3.1 Models Estimation and Evaluation 
The distribution of both the number of medication errors and adverse drug events 
followed the expected count distribution with a large number of zeros, which then 
drastically drops for non zero events, in particular for medication errors.  
 





























 Six different nonlinear regression models for this type of data were evaluated: 
Poisson, Negative Binomial, ZI Poisson, ZI Negative Binomial, Hurdle Poisson and 
Hurdle Negative Binomial. Each model is applied to the four outcomes measures: overall 
errors, overall ADEs, high severity errors and high severity ADEs (category D and 
above). The variable age category was not included in the set of predictors because it was 
not significant in an initial univariate analysis. The three variables included in all the 
models as candidate predictors were: Time, Hospital and Area. A description of each 
variable is presented in Table 3.7.  
 
Table 3.7 Independent Variables 
Variable Description 
T1* equals 1 if the patient stayed in the hospital during period T1, 0 otherwise 
T2* equals 1 if the patient stayed in the hospital during period T2, 0 otherwise 
T3* equals 1 if the patient stayed in the hospital during period T3, 0 otherwise 
T4* equals 1 if the patient stayed in the hospital during period T4, 0 otherwise 
T5* equals 1 if the patient stayed in the hospital during period T5, 0 otherwise 
Hospital equals 1 if the patient stayed at Scottish Rite, 0 if he stayed at Egleston 
Area equals 1 if the patient stayed in the ICU, 0 if he stayed in the GCA 
*The time variables T1-T5 are dummy variables, with T0 as the reference value.  
 
 The time categories represent the patients that were hospitalized during that 
specific period of time. Table 3.8 presents the parts of the EMR system that were live at 
each time period. The ‘x’ indicates that the system functionality was live and the ‘--‘  
indicates that the functionality had not been implemented yet. 
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Table 3.8 Description of the systems implemented at each collection time 
System functionality 
Time Period 
T0 T1 T2 T3 T4 T5 
Epic Rx -- x x x x x 
Smart pumps, eMAR and  clinical ancillary orders -- -- x x x x 
Patient safety initiatives -- -- -- x x x 
RN and MD doc and non-clinical ancillary orders -- -- -- -- x x 
CPOE -- -- -- -- -- x 
 
Medication Errors 
 Table 3.9 presents the parameters estimates and their standard errors for the six 
regression models of all medication errors. An initial evaluation of the models was 
performed by comparing their AIC values (lower is the best), and the following models 
were selected: Poisson, NB, ZIP and ZINB.  Further examination using the likelihood 
ratio test to compare nested models (P vs. NB, ZIP vs. ZINB, and P vs. HP) gave 
significant results for P vs. NB, indicating overdispersion. The Vuong test, used to 
compare non-nested models, was not significant for any of the comparisons: P vs. ZIP, 
NB vs. ZINB and NB vs. HNB. This indicated that a two-part model was not necessary to 
model the high number of zeros in the data. From these tests, we eliminated the zero-
inflated models.  
 The next step in the selection of the best model involves a comparison of the 
fitted and observed values. We observed in Table 3.10 that the Poisson model predicted 
better the number of patients with no medication errors and those with one error. The NB 
model overestimated the number of zeros and underestimated the number of patients with 
one medication error. Therefore, the Poisson model was selected as the best fit to model 
the number of all medication errors.  
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Table 3.9 Parameter estimates and standard errors for all six count models  
Predictor   Poisson NB ZIP ZINB HP HNB 
Poisson or Negative Binomial         
(Intercept)  Coef -5.68 -5.57 -5.07 -5.42 -5.28 -16.45 
  S.E. 0.31 0.35 0.43 0.54 0.76 171.24 
T1 Coef -0.70 -0.78 -0.82 -0.76 -0.55 -0.47 
  S.E. 0.34 0.39 0.38 0.39 0.98 1.22 
T2 Coef -0.61 -0.66 -0.69 -0.65 -0.64 -1.43 
  S.E. 0.34 0.38 0.37 0.40 0.98 1.41 
T3 Coef -0.41 -0.42 -0.46 -0.39 0.05 0.70 
  S.E. 0.30 0.35 0.35 0.37 0.76 1.02 
T4 Coef -2.34 -2.46 -2.46 -2.45 -12.52 -14.44 
  S.E. 0.48 0.50 0.50 0.52 343.23 1430.65 
T5 Coef -2.73 -2.85 -2.82 -2.80 -9.47 -6.78 
  S.E. 0.63 0.65 0.65 0.66 131.68 33.71 
HospitalSR Coef 0.52 0.52 0.71 0.62 
  S.E. 0.22 0.24 0.53 0.29 
Area ICU Coef -0.63 -0.60 -0.87 -0.84 -0.83 -1.51 
  S.E. 0.22 0.25 0.57 0.53 0.54 0.85 
Log(theta)   -0.04 -11.89 
    0.58 171.24 
Logistic model (Zero inflation part)         
(Intercept)  Coef -0.43 -2.42 -2.02 -2.02 
  S.E. 0.84 5.22 0.33 0.33 
T1 Coef -0.66 -0.66 
  S.E. 0.39 0.39 
T2 Coef -0.51 -0.51 
  S.E. 0.39 0.39 
T3 Coef -0.20 -0.20 
  S.E. 0.36 0.36 
T4 Coef -1.76 -1.76 
  S.E. 0.50 0.50 
T5 Coef -2.46 -2.46 
  S.E. 0.65 0.65 
HospitalSR Coef 0.49 1.58 
  S.E. 1.52 4.36 
Area ICU Coef -0.74 -9.57 0.69 0.69 
  S.E. 1.43 169.82 0.25 0.25 
AIC   591.97 584.78 591.30 590.24 613.89 607.43 
Values in bold are significant for p<= 0.05 
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 Hospital type, care area and time periods T1, T4 and T5 were significant in the 
Poisson model (Table 3.9). Patients in the community-based hospital (SR) had a higher 
rate of errors compared to the academic hospital, and patients in the ICUs had a lower 
error rate than those in the GCAs. The latter result might be due to a higher nurse-patient 
ratio in those units as well as the usually higher number of doses per patient in the ICU 
(Table 3.6). The effect of time period was significant for T1 (post EpicRX), T4 (post 
Phys documentation) and T5 (post CPOE). The rate of errors at T1 was reduced by half 
compared to the baseline. During T4 and T5, the errors rate decreased to 10% and 7% of 
the baseline rate, respectively. Reviewing the patient charts, we observed that most of the 
medication errors found at baseline were “order entry errors”, which were completely 
eliminated with the implementation of CPOE. These results confirmed previous studies 
that indicated CPOE as the tool that help decrease medical errors the most [78, 107-109].  
 
Table 3.10 Observed and predicted number of medication errors 
Number of 
errors 
No. of patients 
observed 
No. of patients predicted 
P NB ZIP ZINB HP HNB 
0 857 858 862 861 862 857 857 
1 70 67 58 60 58 74 73 
2 7 9 11 12 11 5 5 
3 2 2 3 3 3 1 1 
4 1 0 1 1 1 0 0 
5 0 0 1 0 0 0 0 
 
 The results from the model estimates can be confirmed in Figure 3.8, which 




Figure 3.8 Box plots of error rates vs. independent variables 
y = log(errors+0.01)-log(doses) 
 
High severity medication errors (D and above) 
Table 3.11 presents the results of the six models for medication errors category D 
and above. Based on the AIC values, the NB and the ZIP are the best-fitting models. The 
ZINB could not be fitted to the data. This happened because for some of the predictors, 
there were so few non-zero values that the parameters of the ZINB could not be 
estimated. For instance, for the Time variables, except for T3, all the rest of them had 
































Table 3.11 Parameter estimates and standard errors for errors D and above 
Predictor   Poisson NB ZIP ZINB HP HNB 
Poisson or Negative Binomial           
(Intercept)  Coef -7.30 -6.99 -4.92 NA -12.70 -19.98 
  S.E. 0.61 0.71 0.76   59.26 39.97 
T1 Coef -1.08 -1.20 -0.45 NA -2.50 -2.25 
  S.E. 0.76 0.87 1.00   323.55 596.08 
T2 Coef -0.48 -0.46 0.21 NA -2.46 -3.49 
  S.E. 0.67 0.77 0.92   424.06 293.25 
T3 Coef 0.57 0.76 -0.21 NA 7.70 9.70 
  S.E. 0.55 0.67 0.77   59.26 40.00 
T4 Coef -2.06 -2.26 -1.98 NA -3.07 -4.87 
  S.E. 0.87 0.97 1.26   272.20 382.14 
T5 Coef -1.34 -1.49 -1.46 NA -2.50 -2.51 
  S.E. 0.76 0.87 1.21   453.78 966.53 
HospitalSR Coef -0.01 -0.42 1.97 NA 11.18 11.96 
  S.E. 0.34 0.42 0.65   323.46 300.96 
Area ICU Coef 0.03 0.05 -2.46 NA -11.99 -15.36 
  S.E. 0.39 0.46 0.67   323.46 300.96 
Log(theta)             NA 
                
Logistic model (Zero inflation part)         
(Intercept)  Coef     1.97 NA -3.85 -3.85 
  S.E.     1.15   0.67 0.67 
T1 Coef     1.14 NA -0.94 -0.94 
  S.E.     1.57   0.78 0.78 
T2 Coef     0.80 NA -0.33 -0.33 
  S.E.     1.32   0.69 0.69 
T3 Coef     -1.46 NA 0.72 0.72 
  S.E.     1.15   0.59 0.59 
T4 Coef     0.15 NA -1.42 -1.42 
  S.E.     1.95   0.88 0.88 
T5 Coef     -0.54 NA -1.00 -1.00 
  S.E.     1.82   0.78 0.78 
HospitalSR Coef     13.15 NA -0.29 -0.29 
  S.E.     143.95   0.37 0.37 
Area ICU Coef     -13.62 NA 1.37 1.37 
  S.E.     143.95   0.46 0.46 
AIC   303.56 289.77 298.05 NA 315.58 302.22 
Results in bold are significant for p<=0.05 
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  The likelihood ratio test comparing the P to the NB model was significant 
(p<0.001), indicating overdispersion. The Vuong test comparing P vs. ZIP was also 
significant, indicating that the overdispersion was due to an unusual high number of 
zeros. Table 3.12 displays the predicted values of each model, and we observed that the 
ZIP predicts better than the NB the non-zero error frequencies. Then, we selected the ZIP 
as the model that best fit the number of medication errors of category D and above.  
 There were no significant factors in the logit part of the ZIP model. Type of 
hospital and area were both significant in the Poisson part of the model. Patients in the 
community-based hospital had a higher rate of errors category D or above, and patients in 
the ICU had a lower rate than those in general care. The results from the model estimates 
can be confirmed in Figure 3.9, which displays the boxplots of the rate of errors for each 
independent predictor. The selection of a ZI model with non significant predictors in the 
logistic part implies that the sample population is heterogeneous, and that there is an 
unobserved group of patients that never experience high category medication errors 
(“fixed” zeros) who we are not able to describe with the current predictors in our model. 
 
Table 3.12 Observed and predicted number of high severity errors 
Number of 
errors D+ 
No. of patients 
observed 
No. of patients predicted 
P NB ZIP ZINB HP HNB 
0 906 903 907 907 NA 906 906 
1 28 31 22 23 NA 28 28 
2 1 3 4 4 NA 1 1 
3 1 0 2 1 NA 0 0 
4 1 0 1 1 NA 0 0 




Figure 3.9 Box plots of high severity errors rates vs. each independent predictor 
y = log(errors_Dplus + 0.01) - log(doses) 
 
Adverse Drug Events 
 Table 3.13 presents the results of the six models for all categories of adverse 
drug events. The models with the best fit, based on their AIC value, were the NB, ZIP, 
ZINB followed by the Poisson model. The result of the test comparing the Poisson to the 
negative binomial model was significant, indicating overdispersion of the observed data. 
The tests comparing the simple models to their zero-inflated counterparts were also 






























Table 3.13 Parameter estimates and standard errors for all ADEs 
Predictor   Poisson NB ZIP ZINB HP HNB 
Poisson or Negative Binomial           
(Intercept)  Coef -5.21 -5.06 -4.28 -4.32 -4.32 -5.66 
  S.E. 0.25 0.29 0.35 0.43 0.37 1.72 
T1 Coef -0.08 -0.02 -0.29 -0.22 -0.31 0.02 
  S.E. 0.28 0.32 0.42 0.52 0.45 0.79 
T2 Coef 0.43 0.50 -0.70 -0.48 -0.90 -0.77 
  S.E. 0.27 0.30 0.36 0.45 0.41 0.72 
T3 Coef 0.48* 0.59 -0.39 -0.19 -0.48 0.05 
  S.E. 0.27 0.30 0.36 0.45 0.37 0.71 
T4 Coef -0.16 -0.14 -1.17 -1.10 -1.65 -1.79 
  S.E. 0.27 0.30 0.38 0.45 0.44 0.73 
T5 Coef -0.05 -0.04 -1.04 -0.97 -1.21 -1.17 
  S.E. 0.27 0.31 0.39 0.16 0.44 0.76 
HospitalSR Coef -0.11 -0.20 0.22 -0.06 0.40 0.28 
  S.E. 0.12 0.13 0.15 0.17 0.20 0.34 
Area ICU Coef -0.66 -0.74 -0.53 -0.61 -0.55 -0.72 
  S.E. 0.12 0.14 0.14 0.16 0.20 0.34 
Log(theta)   1.02 -1.68 
    0.47 2.02 
Logistic model (Zero inflation part)         
(Intercept)  Coef -0.53 -0.69 -1.91 -1.91 
  S.E. 0.78 1.04 0.34 0.34 
T1 Coef -0.46 -0.40 0.17 0.16 
  S.E. 0.74 0.90 0.39 0.39 
T2 Coef -13.11 -16.25 1.05 1.05 
  S.E. 132.35 696.39 0.36 0.37 
T3 Coef -1.88 -1.90 1.13 1.13 
  S.E. 0.71 0.91 0.37 0.37 
T4 Coef -2.86 -10.68 1.07 1.07 
  S.E. 1.22 207.28 0.37 0.36 
T5 Coef -2.46 -3.71 0.68 0.68 
  S.E. 1.25 4.95 0.37 0.37 
HospitalSR Coef 1.33 1.14 -0.60 -0.60 
  S.E. 0.51 0.66 0.16 0.16 
Area ICU Coef 0.69 0.69 0.45 0.45 
  S.E. 0.63 0.80 0.16 0.16 
AIC   1372.20 1344.00 1347.84 1342.91 1427.87 1411.52 
Results in bold are significant for p <= 0.05 
*The p value for the coefficient of T3 was 0.06 
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 However, when looking at how well the models predicted the number of ADEs, 
we observed that the NB and ZI models overestimated the number of zeros and 
underestimated the number of patients with 1 ADE (Table 3.14). The Poisson model 
estimated more accurately the zero and the non-zero counts. Therefore, we selected the 
Poisson model as the best fit for modeling the number of ADEs. 
 
Table 3.14 Observed and predicted number of adverse drug events 
Number of 
ADEs 
No. of patients 
observed 
No. of patients predicted 
P NB ZIP ZINB HP HNB 
0 714 718 729 730 731 714 714 
1 154 155 135 136 132 183 181 
2 43 41 40 43 41 28 27 
3 22 13 16 16 16 7 8 
4 4 5 7 7 7 2 3 
5 0 2 4 0 0 0 0 
6 0 1 2 0 0 0 0 
7 0 1 1 0 0 0 0 
8 0 0 1 0 0 0 0 
9 0 0 1 0 0 0 0 
 
 Only T3 and type of care area were significant in the Poisson model. The 
significant coefficients indicate the rate of ADEs was higher during T3 compared to 
baseline, and it was lower for patients in the ICU compared to those in the GCA. We can 
verify that the model reflects the behavior of the observed data by examining the plots in 
Figure 3.10.  
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Figure 3.10 Bivariate plots of rate of ADEs vs. predictors 
y1=log(ADEs+0.01)-log(Doses) 
 
 Since HITs are supposed to decrease medication errors and ADEs [65, 110], we 
decided to further examine the data to understand what happened during T3. Looking at 
the patient charts, we observed a peak in the number of ADEs identified in the Lab 
Diagnostics, Medications and Nursing ancillary flowsheet sections of the charts (Table 
3.15). We could credit this increase to a better documentation of medications after the 
implementation of the eMAR and ancillary documentation functionalities of the EMR. In 
addition, patient safety initiatives were in place from T3 onwards, which may have also 
encouraged a more accurate reporting and documentation. 
 































Table 3.15 Distribution of ADEs identified in the different chart sections 
Chart Section T0 T1 T2 T3 T4 T5 
Discharge Summary 1 6 4 8 17 14 
H & P 0 0 1 0 1 0 
Lab Diagnostics 2 2 8 17 3 2 
Medications 8 16 26 31 28 20 
Nursing Ancillary Flowsheet 5 8 17 23 0 2 
Operative Record 1 0 3 0 0 0 
Orders 1 4 4 12 15 13 
Total 18 36 63 91 64 51 
 
High Severity ADEs 
Table 3.16 presents the results of the six models for adverse drug events category 
D and above. Following the previous approach to select a model, the models with the best 
fit (lower AIC) are the NB, ZIP and ZINB. The likelihood tests comparing P vs. NB and 
ZIP vs. ZINB were both significant. Likewise, the Vuong test for P vs. ZIP and NB vs. 
ZINB were also significant, indicating that the overdispersion might be due to an excess 




Table 3.16 Parameter estimates and standard errors for ADEs  D+ 
Predictor   Poisson NB ZIP ZINB HP HNB 
Poisson or Negative Binomial         
(Intercept)  Coef -5.33 -5.22 -4.36 -4.58 -4.27 -5.39 
  S.E. 0.27 0.03 0.34 0.49 0.37 1.75 
T1 Coef -0.08 0.02 -0.24 -0.14 -0.34 -0.04 
  S.E. 0.30 0.35 0.42 0.57 0.45 0.82 
T2 Coef 0.03 0.12 -1.07 -0.84 -0.87 -0.68 
  S.E. 0.29 0.35 0.41 0.53 0.45 0.79 
T3 Coef 0.17 0.23 -0.79 -0.55 -0.77 -0.40 
  S.E. 0.27 0.34 0.37 0.52 0.39 0.76 
T4 Coef -0.20 -0.15 -1.18 -0.99 -1.74 -2.02 
  S.E. 0.28 0.33 0.38 0.53 0.46 0.78 
T5 Coef -0.14 -0.15 -1.15 -0.97 -1.16 -1.04 
  S.E. 0.28 0.33 0.40 0.53 0.45 0.79 
HospitalSR Coef -0.03 -0.80 0.50 0.28 0.34 0.09 
  S.E. 0.13 0.16 0.19 0.23 0.23 0.40 
Area ICU Coef -0.62 -0.66 -0.47 -0.50 -0.50 -0.67 
  S.E. 0.13 0.16 0.19 0.20 0.23 0.39 
Log(theta)   0.36 -1.56 
    0.45 2.16 
Logistic model (Zero inflation part)         
(Intercept)  Coef -0.06 -1.13 -2.16 -2.17 
  S.E. 0.70 1.45 0.36 0.37 
T1 Coef -0.35 -0.32 0.19 0.19 
  S.E. 0.66 1.02 0.41 0.41 
T2 Coef -2.59 -15.41 0.52 0.52 
  S.E. 1.39 995.00 0.39 0.40 
T3 Coef -1.78 -2.23 0.79 0.80 
  S.E. 0.73 1.26 0.38 0.39 
T4 Coef -2.17 -2.00 1.04 1.05 
  S.E. 0.78 1.97 0.38 0.38 
T5 Coef -1.90 -2.94 0.55 0.55 
  S.E. 0.94 2.54 0.39 0.39 
HospitalSR Coef 1.33 1.73 -0.39 -0.39 
  S.E. 0.58 0.92 0.17 0.17 
Area ICU Coef 0.35 0.71 0.52 0.52 
  S.E. 0.57 1.00 0.17 0.17 
AIC   1203.80 1162.60 1169.57 1163.35 1233.22 1222.46 
Results in bold are significant for  p<=0.05 
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 When looking at how well the models predicted the actual frequency of ADEs, 
the ZIP estimated more accurately the number of zeros. Similarly, although it 
underestimated the distribution of the non-zeros, the ZIP was the one closer to the actual 
counts (Table 3.17). Therefore, we selected the ZIP model as the best fit to predict the 
frequency of ADEs from categories D and above. The selection of the ZIP model implies 
that the observed data is heterogeneous, with a subgroup of patients that will never 
experience those types of ADEs.   
 
Table 3.17 Observed and predicted number of D+ ADEs 
Number of 
ADEs D+ 
No. of patients 
observed 
No. of patients predicted 
P NB ZIP ZINB HP HNB 
0 761 752 769 767 769 761 761 
1 120 140 111 114 111 145 143 
2 38 32 31 35 33 22 21 
3 17 9 12 13 12 6 6 
4 1 3 6 5 6 2 3 
5 0 1 3 0 0 0 0 
6 0 0 2 0 0 0 0 
7 0 0 1 0 0 0 0 
8 0 0 1 0 0 0 0 
 
 In the logistic component of the ZIP model, hospital type and time periods T2, 
T3, T4 and T5 were significant (see Table 3.16).  The positive coefficient for HospitalSR 
means that patients from Scottish Rite (community-based) had a higher probability of 
belonging to the group that never experiences high severity ADEs. On the contrary, the 
negative coefficients for T2, T3, T4 and T5 indicate that patients hospitalized during 
those time periods have a higher probability of having an ADEs from category D or 
above compared to those at baseline. In the Poisson component, all the predictors were 
significant except for T1. The sign of the coefficients indicates that patients at SR have a 
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higher rate of high severity ADEs compared to patients at EG and that patients in the ICU 
have a lower rate of D+ ADEs compared to those in general care. Similarly, patients 
hospitalized during T2, T3, T4 or T5 had a lower rate of high severity ADEs compared to 
baseline. The effect of the predictors can be verified in the bivariate plots from Figure 
3.11.  
 
Figure 3.11 Bivariate plots of rate of high severity ADEs for each predictor  
y2=log(ADEs+0.01)-log(Doses 
 
 We did not include interaction terms in the regression models for ADEs. 
However, based on the plots of ADEs over time in Figure 3.5 and Figure 3.6, it might be 
a good idea to consider and evaluate interactions between time period and area and 























 A summary of the final models for each outcome measure is presented in Table 
3.18. Despite the high number of zeros observed for the overall medication errors and 
ADEs, a zero-inflated model was not necessary, and a conditional Poisson model 
(conditional on the observed covariates) was enough to describe the observed occurrence 
of events. Warton et al [111] obtained similar results using abundance data. On the other 
hand, high-category events were better described by the zero-inflated Poisson. In this 
case, a zero-inflated model worked because the outcome measure only included those 
events that reached the patient and had the potential to cause harm. Thus, we can argue 
that, for instance, patients with mild conditions or patients of certain age are not at risk of 
ever experiencing those types of medication errors or ADEs.  
 
Table 3.18 Summary of models for errors and ADEs 
Outcome measure Best-fitting model 
Medication errors – all categories Poisson 
Medication errors - categories D and above Zero-inflated Poisson 
Adverse drug events Poisson 
Adverse drug events – categories D and above Zero-inflated Poisson 
  
 
Study Limitations  
 There were a few limitations to this study. First, because of the nature of the EMR 
implementation, it was not possible to isolate and evaluate the individual impact of the 
EMR functionalities (except for the EPICRx, since it was the first one). Therefore, the 
analysis performed only assessed the accumulated effect after each implementation (e.g., 
at T2, we evaluated the impact of EpicRx and eMAR together). In addition, other safety 
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and quality initiatives as well as building expansions that may have taken place during 
the EMR implementation were not included in this study. Thus, their potential effects on 
our outcome measures were not considered 
 Second, in several cases, it was difficult to establish whether a trigger indicated 
the occurrence of an ADE or not. Whenever a reviewer wasn’t sure about the causality of 
an adverse event, it was written off as “Routinary” or “No event”. This may be one 
reason for the low number of ADEs in the data.  
 Third, the use of number of doses as the exposure variable in our models was 
based on the assumption that every dose had the same probability of an error or ADE 
happening. However, in some cases, a number of doses might be administered at once 
(e.g., multi-dose vial or several pills taken at once), which alters the risk of an individual 
dose. Thus, a better way of defining and reporting the rate of events might have been 
using the number of orders, number of patients, patient-days, as seen in other similar 
studies [66, 69]. 
 
3.4 Conclusion 
 We have evaluated the impact on patient safety of the various functionalities of an 
EMR system in an inpatient pediatric setting. In this study, improvements in patient 
safety were represented by reductions in the occurrence of medication errors and adverse 
drug events. Our results indicated that the physician-related functionalities of the EMR 
(physician documentation and CPOE) had the largest effect in decreasing the rate of 
medication errors, which underscores the pivotal role of getting physicians to accept and 
efficiently use technologies such as CPOE. In the case of ADEs, the results suggested 
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that the main contribution of HITs in improving patient safety was in the reduction of the 
initial differences in rates between hospitals and between care areas. These variations 
may have been caused by inconsistencies in the various phases of the medication process 
among settings due to their different organizational cultures. By reducing sources of 
variation, it becomes easier to control and improve outcome measures [112].  
 In the literature review, we found that most healthcare studies examining the rates 
of medication errors and adverse drug events were descriptive in nature. Those 
attempting to model the occurrence or rate of errors or ADEs using statistical analysis 
mainly used logistic regression, which, depending on the underlying distribution of the 
data, might not be appropriate (e.g., if extra zeros are present). If the inappropriate 
distribution is assumed, there is the potential for drawing misleading inferences. Our 
study has contributed to the field by comparing six different nonlinear regression models 
for analyzing medication errors and adverse drug events in a pediatric inpatient facility. 
 When modeling all categories of errors and ADEs, the conditional Poisson 
(conditional on covariates) was the most adequate. The variances of both outcome 
variables were less than double their means, so they weren’t overly dispersed (i.e., no 
need of NB). In addition, the high number of zeros did not appear to be due to extra zeros 
compared to a Poisson distribution, i.e., there was no evidence that the zeros were a 
mixture of two different types. For the case of medication errors and ADEs that reached 
the patient and either harmed him or required an intervention to avoid harm, the ZIP 
model was the best fit. The variances of these observed outcomes were also less than 
double their means, indicating that they weren’t overly dispersed. So again, negative 
binomial models were not necessary. Also, since we were trying to model a specific 
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group of medication errors and ADEs, it was plausible to have a group of patients that 
never experienced those types of high severity events (two types of zeros). In summary, 
for count data with a high number of zeros, if the variance of the outcome variable is less 
than double its mean, then a Poisson model with covariates would be the best fit. In 
addition, if there is apriori knowledge of the potential presence of a subgroup where 
events never occur, then the ZIP model should also be tested. 
 
3.5 Areas for future research 
Areas for future work include: 
• Evaluation of additional covariates such as length of stay and age and two-way 
interaction terms, in particular for ADEs, which presented a lot of variability between 
hospitals and care areas over time. Along the same lines, evaluation of a different set 
of covariates for the logistic part of the zero-inflated models in order to identify the 
at-no-risk populations. 
• Exploration of other variables such as number of orders, patient-days to be used as 
the exposure variable in the count models, and incorporation of number of doses as a 
standard covariate. 
• Investigation of the application of a Bayesian approach to calculate the coefficients of 
the parameter estimates, in particular for the models in which the parameters could 
not be estimated by maximum likelihood procedures. 
• Evaluation of models that take into account covariates that might depend on time, i.e., 
inhomogeneous processes where the rate parameter is a function of time.  
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CHAPTER 4 : IDENTIFICATION OF PREDICTORS OF 
POSTOPERATIVE NAUSEA AND VOMITING 
 
4.1 Literature Review 
4.1.1 Post Operative Nausea and Vomiting 
 Post operative nausea and vomiting (PONV) is a condition that affects patients 
after undergoing surgery. It comprises three main symptoms (i.e., nausea, vomiting, and 
retching) that may occur separately or in combination. Nausea is the sensation of an urge 
to vomit; vomiting or emesis is the forcible expulsion of gastric contents through the 
mouth; and retching is an unproductive effort to vomit [113]. Although it rarely causes 
severe complications, patients are reportedly more afraid of PONV than of post operative 
pain [114]. Other consequences of PONV include increases in medical costs due to 
delays in patient discharge (Habib et al reported a mean delay of 25 min in PACU 
discharge [113]), additional nursing care in the inpatient setting, and unanticipated 
hospital admissions in the ambulatory setting [115-118]. 
 The incidence of PONV is higher for general anesthesia than for regional 
anesthesia [114], however, some procedures such as cesarean section or major orthopedic 
surgeries have presented high rates of PONV after using regional anesthetics [118]. 
Despite our better understanding of PONV and the development of new anti-emetic 
drugs, the overall incidence of PONV remains between 20 and 30%. For high-risk 
groups, the incidence can be as high as 70% [116]. PONV can also occur following 
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discharge from post-anesthesia care units (PACU), even if the patient did not experience 
PONV in PACU [113].    
4.1.2 Risks factors for PONV 
 PONV has a multifactorial origin. Independent risk factors for PONV can be 
classified as follow [114]: 
• Patient-related factors: Well established factors are: gender, smoking status (not just 
smokers, but tobacco users in general [119]), history of PONV or motion sickness, 
and age. The incidence of PONV increases in female patients, in patients with a 
history of PONV or motion sickness and decreases with age (for adults) [117]. 
Factors previously considered, but that have been disproved are body mass index and 
early stage of menstruation cycle [120, 121].  
• Surgical-related factors: type and duration of surgery (higher risk for some 
procedures) are indicated as risk factors for PONV, although there is controversy 
regarding their independence [121, 122] 
• Anesthesia-related factors: administration of volatile anesthetics, opioids, N20 or 
neostigmine can increase the incidence of PONV. Likewise, longer duration of 
anesthesia can increase PONV [117, 123]  
 Another possible predictor is the physical status classification by the American 
Society of Anesthesiologists (ASA) [121]. This is a system for assessing the fitness of 
patients before selecting the anesthetic or performing surgery, but is not intended to 
predict operative risk. It is used by anesthesiologists to classify patients according to their 
medical history. The categories of the ASA system are described in Table 4.1. The 
genetic background of a patient as a risk factor is also starting to be investigated [124]. 
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Table 4.1 ASA physical status classification system 
Category Description 
ASA 1  A normal healthy patient 
ASA 2 A patient with mild systemic disease 
ASA 3  A patient with severe systemic disease 
ASA 4  A patient with severe systemic disease that is a constant threat to life 
ASA 5  A moribund patient who is not expected to survive without the operation 
ASA 6  A declared brain-dead patient whose organs are being removed for donor purposes 
 
 Depending on the surgeries and the populations covered in the reviewed studies, 
the risk factors can vary significantly from one study to another [125]. However, the 
following risk factors have been reported in most studies [126]:  
• gender 
• history of PONV or motion sickness 
• duration of anesthesia 
• non-smoking status 
• use of opioids  
 In most studies of PONV, the outcome analyzed is either vomiting or nausea and 
vomiting together. However, nausea and vomiting have different physiopathologies, 
which mean that they may have different risk factors. For instance, Stadler et al found 
that gender, nonsmoking status, and type of anesthesia were predictive of both nausea 
and vomiting, but type of surgery was associated with nausea but not vomiting [127]. 
4.1.3 Management of PONV 
 New substances have been developed and successfully introduced for the 
prevention and treatment of PONV. These include NK1 receptor antagonists, new 5-HT3 
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receptor antagonists, dimenhydramin, droperidol, dexamethasone, among others [114, 
117, 128]. In order to increase the antiemetic efficacy of single interventions, several 
studies have compared the efficacy of combinations of antiemetic regimens and 
multimodal use of anesthetic techniques [117]. The results show that a combination of 
interventions is more effective than using a single agent (combining interventions has an 
additive effect in risk reduction) [129]. Furthermore, the use of multimodal approaches 
(pharmacologic and nonpharmacologic) to reduce PONV offers additional advantages 
over drug combinations [128, 130].  
 Guidelines for the management of PONV have been developed in the last decade. 
Numerous studies and panels of experts agree that a risk-based approach is the most 
effective strategy for the prevention and treatment of PONV, and can reduce the overall 
institutional rate of PONV [131]. Antiemetics are not universally administered because it 
is not a cost-effective practice and because of their additional adverse effects [132], 
which include increased risk of post operative infection [133]. According to the risk-
based approach, after an initial estimation of the patient’s risk for PONV, only those at 
moderate and high risk should be administered antiemetic prophylaxis. Interventions to 
reduce baseline risk factors should be used first (e.g., avoid inhalational anesthesia which 
has been shown to cause early postoperative vomiting [123]). Depending on the level of 
risk, either a monotherapy or a combination therapy is indicated. Basically, the higher the 
risk of PONV, the greater the number of antiemetic interventions that should be used is 
[134, 135]. A multimodal approach with combinations of antiemetics and 
nonpharmacologic approaches should be considered for patients at high risk of PONV. 
For rescue treatments, the antiemetic administered should be from a different class than 
77 




Figure 4.1 Algorithm for management of PONV [136] 
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4.1.4 Predictive models for PONV 
 A number of predictive models and simplified scoring systems to quantify the 
likelihood of PONV have been developed. Most of them have used logistic regression 
analysis to identify the risk factors for PONV; although there have also been attempts at 
different methodologies such as decision trees [140] and neural networks [141], the latter 
with promising results. Among the most common scores are the Apfel, Koivuranta, 
Palazzo and Evans, and Sinclair scores [121].  
 The formula of the scoring systems for the probability of PONV is: 
            (4.1) 
S  b b x b x … b x        (4.2) 
where P is the probability that a patient will have PONV and -Scoeff is the logistic 
regression equation with the coefficients bi for each predictor variable xi 
 In the Apfel model, the following predictors were identified: gender, history of 
motion sickness or PONV, smoking and use of post operative opioids. The type of 
surgery was not a relevant factor in predicting PONV. 
  2.28  1.27    0.65        
 0.72   0.78          (4.3) 
 A simplified version of this score lets clinicians quantify the risk for PONV by 
counting the number of risk factors present: 10% rate for 0 risk factors, 23% for 1 factor, 
39% when 2 are present, 61% when 3 factors are present and 79% when all 4 factors are 
present [142]. These results have been confirmed by other studies, in which the risk 
scoring system was highly predictive of emetic symptoms within 24 h after surgery (even 
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after multimodal antiemetic prophylaxis); however no correlation was found between the 
Apfel risk score and the incidence of late PONV (> 24 h after surgery) [143]. 
 The Koivuranta scoring system [144] included the following predictors: gender, 
history of PONV, history of motion sickness, non-smoker, and duration of surgery over 
60 min: 
  2.21  0.93    0.82    
0.75    60 min 0.61   
 0.59            (4.4) 
  A simplified version of the Koivuranta score gives the following prediction 
probabilities: 0.17, 0.18, 0.42, 0.54, 0.74, and 0.87 for the presence of 0 to 5 risk factors. 
 A study evaluating the Apfel and the Koivuranta scores found that they do not 
provide accurate prediction of the risk of PONV in populations different to the one used 
to develop the scores [145]. Similarly, Thomas et al reported lack of agreement between 
scoring systems [146]. Comparisons of scoring systems have demonstrated that 
simplified scores are easier to use [147], and provide equal or better discriminating power 
than more complex ones [148-151]. Recommended scoring systems for adults are the 
Apfel and the Koivuranta ones, while the Eberhart simplified system is recommended for 
children [121].  
 The Palazzo & Evans model [152] is effective at estimating the risk of PONV in 
groups of patients, particularly those at high risk [153]. 
5.03 2.34    3.97    
2.4  0.78     
3.2           (4.5) 
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 The Sinclair score [154] identified the following independent predictors: sex, age, 
smoking status, previous PONV, type of anesthesia used, duration of anesthesia, and type 
of surgery. Women and non-smokers had three times more probability of developing 
PONV than men and smokers, respectively. A 10-year increase in age decreased the 
likelihood of PONV by 13%, but only for those older than 50 yr. A 30-min increase in 
the duration of anesthesia increased the likelihood of PONV by 59%. Likewise, general 
anesthesia increased the likelihood of PONV 11 times more than other type of anesthetic 
technique. 
 In her master’s thesis, Velickovic [155] developed a score with three separate 
regressions models for each time interval (0-2, 2-24, 0-24). The factors included in the 
models were: type of surgery (parateoidectomy), history of PONV, BMI, smoking and 
gender. 
0 2 :         0.964 –  2.306   0.938      (4.6a) 
2 24 :      4.482  1: 514   0.062   1.492  (4.6b) 
0 24 :     1.627 –  1.366   1.417   0.525   
 0.864               (4.6c) 
 
A summary of the currently used PONV models is presented in Table 4.2. We observed 
that the number as well as the type of predictors are different for each model and tend to 
be specific to the dataset used to develop the model (e.g., type of surgery in the LELA 
model). Thus, the models are not robust for all populations. 
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Table 4.2 Predictors for five common PONV models 
Models Apfel Koivuranta Palazzo & Evans Sinclair LELA 
# predictors 4 5 5 7 4 
Predictors 












nonsmoking history of motion sickness 
history of 
motion sickness smoking status smoking status 
PO opioid use nonsmoking PO opioid use age 





surgery over 60 
min 




anesthesia used   
      duration of anesthesia   
      type of surgery   
 
4.1.5 Summary of key research needs and study aims 
From the literature review, we extracted the following points: 
• Although several scoring systems have been developed in the last decade, the current 
scoring systems are not robust among populations. Either adjustment of the scoring 
system to the new population, or re-estimation of the regression coefficients is 
necessary to use a previously developed scoring system. 
• Although several studies have proved that adding more risk factors will not increase 
the discriminating power of the current models, there is still more research to be done 
[156] and better antiemetic approaches are still needed [157]. 
  
In this study, we attempt to develop a more accurate but also more general model to 




 The objective in this chapter is to develop a model to predict the risk of having 
PONV during the first 2 hours after surgery (early PONV) and from 2 to 24 hours after 
surgery. 
4.2.1 Data Description 
 The data used for this study came from the database for anesthetic service of the 
Center for Endocrine Surgery in Belgrade, Serbia. It was a retrospective study in which 
471 patients were investigated to identify risk factors for PONV. Patients in the study 
underwent some type of thyroidectomy procedure. Standard anesthetic technique was 
conducted in all patients. The patients were not given antiemetics either in the 
preoperative period or during the surgery. In the case of appearance of two or more 
instances of postoperative nausea and vomiting or after prolonged postoperative nausea, 
antiemetics were given. The monitoring system during the surgery included EKG, pulse 
oximetry, none invasive assessment of blood pressure, and capnography. 
Outcome variables 
 The outcome measure was PONV, a binary variable defined as the existence of at 
least one episode of postoperative nausea, vomiting or nausea and vomiting together. As 
such, it was recorded two times, after 2 hours after surgery and from 2 to 24 hours after 
surgery. 
Potential predictors 
The following variables were investigated for predictive power: 
• Variables related to the patient 
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o Age (yr) 
o Gender 
o History of PONV 
o History of motion sickness 
o ASA classification 
o Smoking status  
o Body mass index (kg/m2) 
• Variables connected with anesthesia:  
o Duration of anesthesia (in min) 
o Number of attempts for intubation 
o Duration of intubation (in min) 
o Time from the end of anesthesia till extubation (in min) 
4.2.2 Analysis Methods 
 An initial assessment to identify associations between predictors and the response 
variable was done using univariate analysis. The continuous variables were analyzed 
using the Student’s t-test and the categorical variables using the χ2 test (2x2 contingency 
tables). In an effort to simplify the interpretation of the final predictive models, some 
continuous variables were transformed into categorical ones. A p-value of <0.05 was 
considered significant. 
 Predictive models using logistic regression models were built for two outcome 
measures: 
• Early PONV: Prediction of PONV during the first 2 hours after surgery 
• Late PONV: Prediction of PONV from 2 to 24 hours after surgery 
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 The categorical predictors were indicated as 1 if present, and 0 if absent (for 
gender, 1 was female, and 0 was male). The inclusion of factors was determined using 
backward stepwise regression; and a p-value less than 0.05 was used as the criterion for 
variables retention. Interaction effects were also examined.  
 Predictive accuracy of the model was assessed by the area under the curve (AUC) 
of the receiving operating characteristic (ROC) curve. Additionally, both PONV models 
were compared to previously developed risk scores: Apfel, Simplified Apfel, Sinclair and 
Lela, using the AUC. All statistical analyses were performed using SPSS Statistics v19.0 
and MATLAB (R2010b).  
 
4.3 Results and Discussion 
 Of the 471 patients, five were excluded because they belonged to category 6 in 
the ASA classification (brain-dead patients). Only patients in category 5 or less were 
included in this study. A total of 466 patients on whom the antiemetic prophylaxis was 
not applied were assessed. 
 Patients’ age varied from 12 to 81 yr (mean = 51.76, SD = 13.65). The female to 
male ratio was 4:1, and about one third of the patients were smokers. Other demographic 
and clinical characteristics of the patients, as well as the distribution of the categorical 






Table 4.3 Descriptive statistics for continuous variables 
Variable 
N 
Mean Std. Deviation Median Min Max Valid Missing 
Age (yr) 466 0 51.76 13.65 54.00 12.00 81.00 
Duration of anesthesia (min) 466 0 78.20 25.84 75.00 20.17 240.00 
Weight (kg) 466 0 73.90 15.39 72.00 38.00 145.00 
BMI (kg/m2) 466 0 26.11 4.64 25.46 15.00 42.39 
Time until extubation (min) 464 2 19.22 133.91 10.00 0.00 2880.00 
 
Table 4.4 Distribution of categorical variables (n=466) 
Variable Frequency Percent 
Gender 
Male 91 19.5 
Female 375 80.5 
Smoking Status 
Smoker 158 33.9 
Non smoker 308 66.1 
History of Motion 
Sickness 
No 440 94.4 
Yes 26 5.6 
History of PONV 
No 409 87.8 
Yes 57 12.2 
Surgery Type 
Lobectomy 4 0.9 
Bilateral subtotal lobectomy 1 0.2 
Total thyroidectomy 300 64.4 
Hemithyroidectomy 92 19.7 
Parathyroidectomy 50 10.7 
Unilateral dissection of neck 5 1.1 
Other 14 3.0 
ASA 
Classification 
1 92 19.7 
2 1 0.2 
3 278 59.7 
4 1 0.2 
5 94 20.2 
Intubation Trials 
1 357 76.6 
2 74 15.9 
3 27 5.8 
4 7 1.5 
5 1 0.2 
Duration of 
Intubation 
1: Standard 429 92.1 
2: Extended 33 7.1 
3: More than 10 min 4 0.9 
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  In order to simplify the use and interpretation of the predictive models, some 
continuous variables were transformed to binary variables (Table 4.5). Based on the risk 
factors identified in previous PONV studies and scores, the following variables were 
added: age over 50, duration of anesthesia over 75 min, BMI over 30 (or obese). 
Likewise, ASA physical status classification was reduced to only 2 categories: one 
including the original categories 1, 2 and 3 (better health status) and another one for 
categories 4 and 5. 
 
Table 4.5 Distribution of new categorical variables (n=466) 
Variables Frequency Percent 
Age over 50 
No 189 40.6 
Yes 277 59.4 
BMIGR2 
Not obese 384 82.4 
Obese 82 17.6 
Duration of anesthesia 
over 75 min 
No 252 54.1 
Yes 214 45.9 
ASAclass2 
0: Cat 1-3 371 79.6 
1: Cat 4-5 95 20.4 
Duration Intubation2 
Standard 429 92.1 
Extended 37 7.9 
 
 More patients experienced early PONV than late PONV. More than a quarter of 
the patients (27.3%) had at least one episode of PONV during the first two hours after 
surgery, while only 21.5% experienced PONV during the next 22 hours (Table 4.6).  
 
Table 4.6 Observed incidence of PONV (n=466) 
Outcome Variable Frequency Percent 
PONV within 2 hr 
after surgery 
No 339 72.7 
Yes 127 27.3 
PONV from 2 to 24 hr 
after surgery 
No 366 78.5 
Yes 100 21.5 
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4.3.1 Exploratory analysis of predictors 
Continuous predictors 
 Continuous variables were evaluated using the t test. No significant differences 
between patients with and without PONV episodes (for both early and late PONV) were 
identified at α=0.05. However, for late PONV, duration of anesthesia and BMI had p-
values of 0.06 and 0.078, respectively, and thus were included as initial predictors in the 
logistic regression models (Table 4.7).  
 
Table 4.7 Results from t-test for continuous variables 
Group   Age Duration of anesthesia Weight BMI 
Time until 
extubation 
PONV 0 to 2 
t 0.977 -0.088 1.461 -0.032 0.593 
df 464 312.516 464 464 462 
p-value 0.329 0.93 0.145 0.975 0.554 
PONV 2 to 24 
t -0.878 -1.884 0.401 -1.767 0.468 
df 464 464 464 464 462 
p-value 0.38 0.06 0.689 0.078 0.64 
 
Categorical Predictors 
 The Pearson Chi-square test for independence between binary categorical 
predictors and early PONV was statistically significant for gender (χ2=5.334, p=0.025), 
history of PONV (χ2=13.254, p<0.001), and ASA classification (χ2=6.524, p=0.014) 
(Table 4.8). Similarly, statistically significant associations were identified between late 
PONV and the following categorical variables: gender (χ2=12.716, p<0.001), history of 
PONV (χ2=25.866, p<0.001), duration of anesthesia over 75 min (χ2=10.16, p=0.002), 
and early PONV (χ2=27.642, p<0.001) (Table 4.9).  
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 All categorical variables with p value less than 0.5 were included as initial 
predictors in the logistic regression models for both early and late PONV. 
 
Table 4.8 2x2 Contingency tables for early PONV 
Variable 
PONV0to2 
Total Pearson Chi-Square p-value no yes 
gender 
male 75 16 91 
5.334 .025 female 264 111 375 
Total 339 127 466 
ageover55 
no 178 69 247 
0.123 .755 yes 161 58 219 
Total 339 127 466 
BMIGR2 
Not obese 277 107 384 
0.411 .586 Obese 62 20 82 
Total 339 127 466 
Smoking 
yes 121 37 158 
1.774 .189 no 218 90 308 
Total 339 127 466 
HistMS 
no 320 120 440 
0.002 1.000 yes 19 7 26 
Total 339 127 466 
HistPONV 
no 309 100 409 
13.254 .000 yes 30 27 57 
Total 339 127 466 
Duranesover75 
no 189 63 252 
1.405 .252 yes 150 64 214 
Total 339 127 466 
ASAclass2 
0: Class 4-5 79 16 95 
6.524 .014 1: Class 1-3 260 111 371 
Total 339 127 466 
DurIntub2 
0: Standard 315 114 429 
1.259 .335 1: Extended 24 13 37 
Total 339 127 466 
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Table 4.9 Contingency tables for late PONV 
Variable 
PONV2to24 
Total Pearson Chi-Square p-value no yes 
gender 
male 84 7 91 
12.716 0.000 female 282 93 375 
Total 366 100 466 
ageover55 
no 196 51 247 
0.205 0.653 yes 170 49 219 
Total 366 100 466 
BMIGR2 
Not obese 307 77 384 
2.564 0.137 Obese 59 23 82 
Total 366 100 466 
Smoking 
yes 131 27 158 
2.709 0.121 no 235 73 308 
Total 366 100 466 
HistMS 
no 345 95 440 
0.081 0.815 yes 21 5 26 
Total 366 100 466 
HistPONV 
no 336 73 409 
25.866 0.000 yes 30 27 57 
Total 366 100 466 
duranesover75 
no 212 40 252 
10.16 0.002 yes 154 60 214 
Total 366 100 466 
ASAclass2 
0: Class 4-5 80 15 95 
2.276 0.161 1: Class 1-3 286 85 371 
Total 366 100 466 
DurIntub2 
0: Standard 336 93 429 
0.154 0.836 1: Extended 30 7 37 
Total 366 100 466 
Headache0to2 
no 335 90 425 
0.229 0.690 yes 31 10 41 
Total 366 100 466 
PONV0to2 
no 287 52 339 
27.642 0.000 yes 79 48 127 
Total 366 100 466 
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4.3.2 Logistic Regression models 
Model for early PONV (0 to 2 hr after surgery) 
 The following predictors were evaluated as independent variables in the model for 
early PONV: gender, smoking, HistPONV, duranesover75, ASAclass2, DurIntub2 and 
BMI. The following variables met the criteria for inclusion when alpha was set to 0.05: 
Gender, ASA physical status, and history of PONV. From Table 4.10, we observed that 
the odds of developing an episode of PONV during the first 2 hours after surgery was 
almost double for women that for men (OR=1.768). Likewise, the odds for patients with 
history of PONV were 2.477 times higher than for those with no previous history of 
PONV. Lastly, a patient with a better physical status (ASA 1-3), had about twice the odds 
(OR=1.892) of developing early PONV that one classified in either category 4 or 5. 
 
Table 4.10 Logistic regression model for early PONV - 3 predictors 
Variable B S.E. Wald df Sig. Exp(B) 
95% CI for Exp(B) 
Lower Upper 
Gender female 0.570 0.303 3.534 1 0.060 1.768 0.976 3.203 
Better physical status 0.638 0.302 4.471 1 0.034 1.892 1.048 3.418 
HistPONV 0.907 0.292 9.620 1 0.002 2.477 1.396 4.395 
Constant -2.097 0.377 30.850 1 0.000 0.123     
 
 When the inclusion criteria α was increased to 0.1, patients’ smoking status 
(variable Nonsmoking) was also included in the model (see Table 4.11). The odds ratio 
for nonsmokers was 1.5 times higher than for smokers. The odds and coefficients for the 
previously selected predictors changed minimally.  
 
91 
Table 4.11 Logistic regression model for early PONV  - 4 predictors 
Variable B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Gender female 0.565 0.304 3.452 1 0.063 1.760 0.969 3.196 
NonSmoking 0.407 0.234 3.030 1 0.082 1.502 0.950 2.376 
HistPONV 0.903 0.294 9.418 1 0.002 2.466 1.386 4.389 
Better physical status 0.683 0.304 5.047 1 0.025 1.979 1.091 3.590 
Constant -2.408 0.424 32.322 1 0.000 0.090     
 
 Several models with different 2-way interaction terms were also evaluated. The 
interaction terms Gender*Duranover75, Gender*Ageover55 and Ageover55*HistPONV 
were significant at α = 0.1 (one interaction effect per model). Only the model including 
the interaction Gender*Ageover55 (Table 4.12) also improved on the value of the AUC. 
 
Table 4.12 Logistic regression model for early PONV – 5 predictors 
Variable B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Gender female 0.072 0.363 0.039 1 0.843 1.075 0.528 2.189 
HistPONV 0.937 0.295 10.094 1 0.001 2.551 1.432 4.546 
Better physical status 0.694 0.315 4.861 1 0.027 2.002 1.080 3.710 
Ageover55 -1.291 0.690 3.503 1 0.061 0.275 0.071 1.063 
Female*over55 1.520 0.728 4.368 1 0.037 4.574 1.099 19.038 
Constant -1.772 0.423 17.514 1 0.000 0.170     
 
 The values of the AUC for the models with 3, 4 and 5 predictors were 0.617, 
0.634 and 0.642, respectively. The ROC curves for each model are displayed in Figure 
4.2. Based solely on the AUC, the model with 5 predictors would be the best option. 
However, many times we are also interested in the model performance above a minimum 
sensitivity or specificity value. In this particular study, and to simplify the calculations, 
we assigned minimum sensitivity and specificity values of 60% and 30%, respectively. 
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Assuming that sensitivity and specificity are equally important, the model with the 
optimal sensitivity-specificity combination would be the one with the largest distance to 
the reference line. 
 
 
Figure 4.2 ROC curves for early PONV models with 3, 4 and 5 predictors 
 
 For each curve, its AUC and the coordinate with the largest distance to the 
reference line, within the specified sensitivity-specificity range, are presented in Table 
4.13. The model with 4 predictors had the largest distance, and was therefore selected as 
the best model to predict early PONV.  
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Table 4.13 Best sens-spec combinations for sensitivity >= 60% 
Model AUC Cutoff value Sensitivity Specificity 
Distance to 
reference line 
3 predictors 0.617 0.24 0.787 0.363 0.106 
4 predictors 0.634 0.26 0.630 0.590 0.155 
5 predictors 0.642 0.26 0.787 0.372 0.112 
 
The final model for early PONV can be expressed as: 
1 2.408 0.565 0.407  
                                                   0.683 2 0.903   
Where p = probability of having an episode of PONV during the first 2 hr after surgery, 
is: 
0.09 1.76 1.502 1.979 2.466
1 0.09 1.76 1.502 1.979 2.466  
 
Models for late PONV (2 to 24 hr after surgery) 
 The following predictors were included in the final model: gender female, 
previous history of PONV, whether they had PONV during the first 2 hr after surgery, 
duration of anesthesia over 75 min and body mass index (in Table 4.14).  The presence of 
each predictor increases the likelihood of having late PONV. For BMI, the odds increase 
in 5% per each unit increase. The AUC for the ROC curve of this model is 0.75. 
 Another model using the categorical representation of BMI (BMIGR2), which 
differentiates obese vs. not obese patients, was also evaluated. Additionally, and in an 
effort to make the model more applicable to other populations, we replace the categorical 
variable ‘Duranesover75’ for the continuous predictor ‘Duration of anesthesia’. The 
results of this model are presented in Table 4.15. The AUC for this model was 0.738.  
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 An even simplified version without the predictor ‘duration of anesthesia’ was also 
examined (Table 4.16). The AUC for this model was 0.728.  
 
Table 4.14 Model for late PONV (4 cat pred + BMI) 
Variable B S.E. Wald df Sig. Exp(B) 
95% C.I.for Exp(B) 
Lower Upper 
Gender female 1.379 .451 9.347 1 .002 3.969 1.640 9.607 
HistPONV 1.204 .322 13.978 1 .000 3.333 1.773 6.265 
PONV0to2 1.012 .253 15.989 1 .000 2.750 1.675 4.516 
DurAnesover75 .615 .249 6.114 1 .013 1.849 1.136 3.009 
BMI .051 .027 3.692 1 .055 1.053 .999 1.109 
Constant -4.702 .863 29.652 1 .000 .009     
 
Table 4.15 Model for late PONV (4 cat pred + DurAnesthesia) 
Variable B S.E. Wald df Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Gender female 1.410 .452 9.730 1 .002 4.097 1.689 9.939 
HistPONV 1.265 .320 15.628 1 .000 3.543 1.892 6.633 
PONV0to2 1.037 .253 16.859 1 .000 2.821 1.719 4.627 
DurAnesthesia .009 .005 3.841 1 .050 1.009 1.000 1.019 
BMIGR2 .594 .307 3.738 1 .053 1.811 .992 3.305 
Constant -3.945 .615 41.096 1 .000 .019 
 
Table 4.16 Model for late PONV with 4 categorical predictors 
Variable B S.E. Wald df Sig. Exp(B) 
95% C.I.for Exp(B) 
Lower Upper 
Gender female 1.355 .450 9.081 1 .003 3.876 1.606 9.357 
HistPONV 1.287 .318 16.433 1 .000 3.623 1.944 6.751 
PONV0to2 1.037 .251 17.087 1 .000 2.819 1.725 4.609 
BMIGR2 .661 .304 4.725 1 .030 1.937 1.067 3.515 





Figure 4.3 presents the ROC curves for all three models for late PONV. 
 
Figure 4.3 ROC curves for models of late PONV 
 
 In addition to the AUC for each models, we also identified the model with the 
best sensitivity-specificity combination for a particular range. In this case, since the 
values of AUC are higher than for early PONV, we assigned a minimum value of 65% 
for both sensitivity and specificity. We calculated the largest distance to the reference line 
for each model, and obtained their optimal sensitivity-specificity combinations. The 
results are presented in Table 4.17. We observed that there is not much difference among 
the distances of the models; thus, in the interest of parsimony, we selected the model with 
4 predictors as the optimal predictive model for late PONV. 
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Table 4.17 Best sens-spec combinations for sensitivity >= 65%  
Model AUC Cutoff value Sensitivity Specificity 
Distance to 
reference line 
4 cat  predictors 0.728 0.23 0.677 0.681 0.253 
4 cat predictors + Duranes 0.738 0.20 0.677 0.690 0.259 
4 cat predictors + BMI 0.750 0.21 0.687 0.698 0.272 
 
The final model for late PONV can be expressed as: 
1 3.165 1.355 0.661 2 
                                                   1.287 1.037 0 2  
Where p = probability of having at least one episode of PONV between 2 and 24 hr after 
surgery: 
0.042 3.876 1.937 3.623 2.819
1 0.042 3.876 1.937 3.623 2.819  
 
Comparison with other Scores 
 Both the early and late PONV models were compared to the LELA scores, which 
were developed using the same patient database.  
 The AUC values and ROC curves for the early PONV models are presented in 
Table 4.18 and Figure 4.4. The model with 4 predictors has the highest AUC. The Lela 
score has the advantage of having only 2 predictors; however, one of them is surgery-
related and specific to the population used to develop the score. Thus, it makes it less 
applicable to use with other populations. Our model, although with two more predictors, 
uses general categorical patient-related variables which can be easily calculated to 
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determine the patient risk for PONV. Additionally, it’s easy to see that the model with 4 
predictors has the best sensitivity- specificity combination for sensitivity > 60%. 
Table 4.18 Comparison of early PONV models with LELA score 
Model AUC 
PONV0to2 - 4 predictors 0.634 
PONV0to2 - 3 predictors 0.617 
Lela Score for PONV0to2 0.615 
 
 
Figure 4.4 ROC curves comparing models for early PONV vs. Lela score  
 
 Additionally, our model for early PONV was also compared to other well known 
PONV scores. The model with 4 predictors was better than the Sinclair, Apfel and the 
simplified Apfel. The AUC values and ROC curves for all the models are shown in Table 
4.19 and in Figure 4.5. 
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Table 4.19 AUC for models of early PONV  
Model AUC 
PONV0to2 - 4 predictors 0.634 
Sinclair calculated probability 0.560 
Apfel calculated probability 0.595 
Apfel Score 0.597 
 
 
Figure 4.5 ROC curves comparing early PONV model to Apfel & Sinclair scores 
 
 In a similar fashion, the selected regression model for late PONV was also 
compared with the LELA, Apfel, Sinclair and simplified Apfel scores. The results in 
Table 4.20 show that our model is the best one with the highest AUC value, followed by 
the LELA score. The Sinclair and Apfel scores have AUC values lower than 65%. As in 
the case with early PONV, the LELA score for late PONV has fewer predictors (3), but 
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includes a categorical variable for type of surgery and a continuous variable for BMI. Our 
model has 4 predictors, but they are all categorical, which makes it easier to develop a 
simplified score. Furthermore, the ROC curves in Figure 4.6 show that our model with 4 
predictors also has the best sensitivity-specificity combination. 
 
Table 4.20 AUC for models of late PONV  
Model AUC 
Late PONV - 4 predictors 0.725 
LELA score for PONV2to24 0.690 
Sinclair calculated probability 0.602 
Apfel calculated probability 0.637 
Apfel Score 0.648 
 
 




 In both the early and late PONV models, the most important predictor of PONV 
was previous history of PONV. For early PONV, ASA physical status was also a 
significant predictor. We found only one study [121] that mentioned better ASA physical 
status as a possible risk factor for PONV. Our results make stronger the case for 
including the patient’s ASA physical status as a risk factor for early PONV.   
 For late PONV, not only previous history of PONV was a significant predictor, 
but also early PONV. This is worth noting because if a patient did not have an episode of 
PONV during the first 2 hours, then is most likely that he/she would not experience 
PONV in the next 22 hours. Although BMI was discarded as a risk factor in several 
studies, our research found it to be a strong predictor of later PONV, with obese patients 
having less probability than not obese patients of developing PONV. Often cited risk 
factors such as age or length of surgery were not significant in our study.  
 Our model was stronger than previously developed scores. Another advantage of 
the developed models is that the significant predictors in both early and late PONV 
models are factors that can be easily assessed before surgery to obtain the patient 
probability of developing PONV.  
 Some limitations of this study were:  
• The patients included in this study underwent some type of thyroidectomy. Thus, 
although we tried to make the model more general by not including the type of 
surgery, our model might not work as well for patients undergoing other type of 
surgeries. 
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• There was no record of the number of PONV episodes a patient experienced; 
therefore, we didn’t have data on whether a patient was given antiemetics during the 
first 2 hours after surgery. This could have an effect on the significance of early 
PONV on later PONV that we did not consider. 
 Future work includes: 
• Evaluate the robustness of the models and its independence from surgery type with an 
independent dataset  
• Investigate the significance of early PONV in the late PONV with additional data on 
whether a patient was given antiemetics during the first 2 hours after surgery  
• Develop a model for PONV during the entire 24 hours after surgery and also 




CHAPTER 5 CONCLUSION 
 
This thesis deals with the application of predictive modeling and data mining to 
analyze and interpret three types of data found in healthcare and clinical research. The 
first study involves the assessment of hydration status using breath analysis. Through 
analysis of the more than 300 volatile organic compounds contained in exhaled human 
breath, we proposed to identify markers of hydration. With a sample size of 36 subjects, 
this requires the use of methods to solve a “large p, small n” problem. The motivation 
behind this study is that current hydration assessment methods are either, accurate and 
invasive (e.g., urine osmolality), or not invasive and also not very accurate (e.g., change 
in body mass). On the other hand, breath tests are inexpensive, noninvasive and easy to 
perform, and would be a better alternative to current hydration measurement methods. 
  Breath test data consist of a large number of volatile organic compounds 
(VOCs), serving as potential predictors and biomarkers. A methodology to reduce the 
number of VOCs is developed by correlating each of them with a “hydration profile” 
based on the subjects’ hydration probabilities. We further apply principal component 
analysis and support vector machines and build a classifier to discriminate between the 
euhydrated and the 24-hr dehydrated group. The classification rate is 73.89%, which is 
low when compared to two other well-known markers of hydration: Uosm and Posm. The 
former provides almost a 100% classification rate, and the latter has 82%. Although our 
results do not provide an improvement on other hydration measures, this study was the 
first to explore the application of breath analysis to measure hydration status. Future 
research includes the identification of the VOCs associated to the dehydration process 
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and the evaluation of other potential measures of hydration status such as fingerstick Posm 
(compared to venipuncture). 
 
 For the second problem, we develop a mathematical model to evaluate the impact 
of an electronic medical record system on the occurrence of medication errors and 
adverse drug events in a pediatric inpatient setting. In this chapter, we deal with count 
data that has a very large number of zeros and provide a methodology to model and select 
the most appropriate model. The first step in model selection is to obtain the mean-
variance relationship of the data. If the variance is less than twice the mean, then the data 
is not overly dispersed and can be fit with a Poisson model. Next, if we have some 
knowledge about the presence of a group with “always” zeros, then the ZIP or HP should 
be evaluated. This methodology can be applied to other count data with excess zero, and 
the models can be extended by adding other covariates, including interaction terms. 
 This study also increases the knowledge base of implementing HITs by 
developing a better understanding of the impact of an incremental EMR implementation 
on patient safety, measured by the change in the rate of medical errors and adverse drug 
events. Our results of the data modeling indicate that HITs, in particular physician 
documentation and CPOE, reduce the rate of medication errors across hospitals and care 
areas. In the case of ADEs, the contribution of HIT is on the reduction of sources of 
variation of ADEs.  
 
In the last chapter, we use predictive modeling to identify the risk factors and 
estimate a patient probability of developing post-operative nausea and vomiting based on 
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her demographics and clinical history. We develop several linear regression models to 
predict both, early and late PONV and then select the best one based on their AUC values 
and on their sensitivity-specificity combination. The latter criterion is particularly useful 
because it allows the evaluation of the models within specific ranges (e.g., be able to 
predict with at least 60% sensitivity). The predictors in our final models are not specific 
to the dataset used to develop the model, which is an advantage over other previously 
developed PONV models and scores. Another benefit of our models is that the significant 
predictors in both early and late PONV models are variables that can be easily gathered 
from the patient medical history before surgery to obtain the patient probability of 
developing PONV. These are: previous history of PONV, gender, ASA physical status, 
and obesity. For late PONV, early PONV was also a strong predictor. This is very 
relevant because if a patient did not have an episode of PONV during the first 2 hours, 
then it is most likely that she won’t experience PONV in the next 22 hours. This factor 
had not been considered in any other PONV models. 
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